var title_f35_44_36544="Breast MRI intraductal papilloma";
var content_f35_44_36544=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Breast MRI intraductal papilloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T1-weighted precontrast image (A) demonstrates a dilated duct containing proteinaceous or hemorrhagic debris (green arrow). Following IV contrast, an enhancing mass is seen contiguous to the dilated duct (B; red arrow). This was biopsied under MR guidance and shown to represent an intraductal papilloma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Priscilla J Slanetz, MD, MPH, FACR.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_44_36544=[""].join("\n");
var outline_f35_44_36544=null;
var title_f35_44_36545="Rhagades";
var content_f35_44_36545=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital syphilis: Rhagades",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph demonstrates rhagades, which are cracks or fissures in the skin around the mouth, in a patient with late congenital syphilis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: the Public Health Image Library, Centers for Disease Control and Prevention. Photo by Susan Lindsley.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_44_36545=[""].join("\n");
var outline_f35_44_36545=null;
var title_f35_44_36546="Koilonychia 1";
var content_f35_44_36546=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Koilonychia (spoon nail) associated with iron deficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Moise L Levy, MD. Reproduced with permission from: Chung EK, Boom JA, Datto GA, Matz PS. Visual Diagnosis in Pediatrics. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_44_36546=[""].join("\n");
var outline_f35_44_36546=null;
var title_f35_44_36547="Palpation of scaphoid in anatomic snuffbox";
var content_f35_44_36547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palpation of the scaphoid in anatomic snuffbox",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A good method for evaluating the body of the scaphoid is to gently bring the patient&rsquo;s wrist into ulnar deviation and slight volar flexion, and then, palpate the anatomic snuffbox. The snuffbox lies&nbsp;between the extensor pollicis longus tendon medially and extensor pollicis brevis and abductor pollicis longus tendons laterally.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_44_36547=[""].join("\n");
var outline_f35_44_36547=null;
var title_f35_44_36548="Pertuzumab: Patient drug information";
var content_f35_44_36548=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pertuzumab: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/61/25557?source=see_link\">",
"     see \"Pertuzumab: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14476879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Perjeta&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F14473056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F14473057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691765",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat breast cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F14473004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3804513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pertuzumab or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F14473006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698509",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a heart function test. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3516750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A tumor sample test will be done to see if you can take this drug. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697725",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust during care and for 6 months after care ends.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F14473121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697868",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia and low white blood cell count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Good mouth care may help. Ask the doctor for a drug to help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698240",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or mouth sores.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14473007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F14473059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F14473008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85640 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-202.43.93.2-77D3A94D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_44_36548=[""].join("\n");
var outline_f35_44_36548=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14476879\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473056\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473057\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473004\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473006\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473121\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473007\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473059\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473008\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/61/25557?source=related_link\">",
"      Pertuzumab: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_44_36549="Age-related bone loss";
var content_f35_44_36549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F64827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F64827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Age-related bone loss",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 566px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The mg of hydroxyapatite lost with age was measured using high resolution peripheral CT of the distal radius in a cross-sectional study of 122 white women with a mean age of 62.8 (range 27 to 98) years. Please note that most bone lost after the age of 65 was cortical. Cortical porosity was measured using scanning electron microscopy of post-mortem specimens of femora from 24 women with a mean age of 69 (range 29 to 99) years and is depicted in a schematic fashion.",
"    <div class=\"footnotes\">",
"     * p&lt;0.0001.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Zebaze RM, Ghasem-Zadeh A, Bohte A, et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: A cross-sectional study. Lancet 2010; 375:1729. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_44_36549=[""].join("\n");
var outline_f35_44_36549=null;
var title_f35_44_36550="Pipotiazine: Drug information";
var content_f35_44_36550=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pipotiazine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/21/39252?source=see_link\">",
"    see \"Pipotiazine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F210521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Piportil&reg; L",
"      <sub>",
"       4",
"      </sub>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F210535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antipsychotic Agent, Typical, Phenothiazine, Piperidine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F210525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Schizophrenia (maintenance treatment):",
"     </b>",
"     I.M.: Initial (dosage must be individualized): 50-100 mg; may be increased in 25 mg increments every 2-3 weeks. Optimal dosage and interval must be determined by individual response. Usual maintenance dose: 75-150 mg every 4 weeks; range: 25-250 mg every 3-4 weeks. A lower dose at a shorter interval (eg, every 3 weeks) may be beneficial in some patients compared to higher doses every 4 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F210526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     &gt;50 years: Initial dosage &lt;50 mg is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10076328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, oil, as palmitate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Piportil&reg; L",
"     <sub>",
"      4",
"     </sub>",
"     : 25 mg/mL (1 mL) [contains sesame oil]; 50 mg/mL (1 mL, 2 mL) [contains sesame oil]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F210508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by intramuscular injection only using at least a 21-gauge needle for injection. Use a dry syringe and needle for administration; a wet needle/syringe may cause the solution to become cloudy.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F210507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintenance treatment of schizophrenia",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F210533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest, ECG changes, edema, hypotension, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, syncope, tachycardia, venous thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, cerebral edema, depression, dizziness, drowsiness, EEG changes, extrapyramidal symptoms (akathisia, dyskinesia, dystonia, hyper-reflexia, oculogyric crisis, opisthotonos, pseudoparkinsonism, rigidity, sialorrhea, tremor), headache, insomnia, paradoxical psychosis, restlessness, seizure, tardive dyskinesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, eczema, epithelial keratopathy erythema, exfoliative dermatitis, dermatitis, photosensitivity, pruritus, rash, seborrhea, skin pigmentation (prolonged therapy), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Galactorrhea, glucose intolerance, gynecomastia, hyperglycemia, menstrual irregularities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Adynamic ileus, anorexia, fecal impaction, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Bladder paralysis, impotence, incontinence, priapism, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, eosinophilia, leukopenia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Biliary stasis, cholestatic jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, corneal deposits (prolonged therapy), glaucoma, lenticular deposits, pigmentary retinopathy (prolonged therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pneumonia, pneumonitis, pulmonary embolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased, lupus-like syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F210511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pipotiazine, phenothiazine derivatives, or any component of the formulation (cross-reactivity between phenothiazines may occur); severe CNS depression; suspected or established subcortical brain damage; psychoneurotic patients or geriatric patients with confusion and/or agitation; hepatic or renal dysfunction; circulatory collapse; severe cardiovascular disorder; severely depressed patients; high doses of hypnotics; blood dyscrasias; altered states of consciousness or coma (particularly when due to intoxication with CNS depressant drugs [eg, hypnotics, narcotics, ethanol]); pheochromocytoma; use in children",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F210496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction and prolong QT interval; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics, but risk may be increased with doses exceeding recommendations. Use with caution or avoid use in patients with electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), hypothyroidism, familial long QT syndrome, concomitant medications which may augment QT prolongation, or any underlying cardiac abnormality which may also potentiate risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: Phenothiazines may cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Use in patients with blood dyscrasias is contraindicated; monitor blood counts periodically and discontinue at first signs of blood dyscrasias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (ie, Alzheimer's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms: Compared to some other phenothiazines, use has been associated with a higher incidence of extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia. Consider discontinuation of therapy with signs/symptoms of tardive dyskinesia; the lowest effective dose or shortest duration of treatment should be used to minimize risk of tardive dyskinesia. Persistent tardive dyskinesia may also occur, particularly with long-term therapy or following discontinuation of therapy; in some patients, tardive dyskinesia may be irreversible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): May be associated with NMS; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability (risk may be increased in patients with Parkinson's disease or Lewy body dementia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Prolonged therapy may cause pigmentary retinopathy, corneal deposits, and/or changes in skin pigmentation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolism: Cases of venous thromboembolism, DVT, and pulmonary embolism have been reported with antipsychotics; use caution in patients with risk factors for thromboembolism or stroke.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia: Antipsychotics increase the risk of death in elderly patients with dementia-related psychosis. Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Pipotiazine is not approved for the treatment of dementia or dementia-related psychosis in elderly patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Glucose intolerance or hyperglycemia has been reported with use; use caution in patients with diabetes or at risk for diabetes; monitor serum glucose levels during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade. Screening is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease; they may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prolactin-dependent tumors: Use with caution in patients with breast cancer or other prolactin-dependent tumors; elevates prolactin levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiemetic effects: May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor) due to antiemetic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; older adults are at increased risk for developing adverse effects. The elderly may also be at increased risk for developing tardive dyskinesia, particularly females or those on higher doses. Lower doses are recommended for older adults &gt;50 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depot injections: Adverse effects of depot injections may be prolonged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sesame oil: May contain sesame oil; use with caution in patients with known allergy to sesame oil or similar compounds.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F210531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F210500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). Specifically, this may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. Antidepressants (Serotonin Reuptake Inhibitor/Antagonist) may enhance the hypotensive effect of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antimalarial Agents: May increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F210518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid kava kava, valerian, St John's wort, gotu kola (may increase CNS depression). Avoid dong quai, St John's wort (may also cause photosensitization).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F210512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F210503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; liver function test and CBC with differential (at baseline and then periodically during therapy, particularly during the first 2-3 months of therapy); electrolytes; renal function (with long-term therapy); serum potassium and magnesium, fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     ; waist circumference, BMI; mental status, abnormal involuntary movement scale (AIMS); periodic eye exam",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Based on experience with other piperidine phenothiazines: consider baseline and periodic ECG, do not initiate if QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;450 msec",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F210513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Longum 4 (NL);",
"     </li>",
"     <li>",
"      Lonseren (ES);",
"     </li>",
"     <li>",
"      Ni Meng Shu (CL);",
"     </li>",
"     <li>",
"      Piportil (BR, FR, HN, NO, NZ, PL, RU, SG);",
"     </li>",
"     <li>",
"      Piportil Depot (AU, GB, ZA);",
"     </li>",
"     <li>",
"      Piportil L4 (AR, BR, CN, CO, FR, MX, PE, PL, PY, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F210495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks postsynaptic mesolimbic dopaminergic receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones. Relative to other piperidine phenothiazines, pipotiazine appears to be less sedating, with less potential to potentiate other CNS depressants, and may possess a lower propensity to cause hypotension. However, it has a relatively high propensity for cause extrapyramidal reactions. Pipotiazine palmitate is an ester of pipotiazine with a prolonged duration of action.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F210510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.M.: 2-3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 3-6 weeks",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dencker SJ, Frankenberg K, Malm U, et al, \"A Controlled One-Year Study of Pipotiazine Palmitate and Fluphenazine Decanoate in Chronic Schizophrenic Syndromes. Evaluation of Results at 6 and 12 Months' Trial,\"",
"      <i>",
"       Acta Psychiatr Scand Suppl",
"      </i>",
"      , 1973, 241:101-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/44/36550/abstract-text/4147508/pubmed\" id=\"4147508\" target=\"_blank\">",
"        4147508",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gill SS, Bronskill SE, Normand SL, et al, \"Antipsychotic Drug Use and Mortality in Older Adults With Dementia,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2007, 146(11):775-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/44/36550/abstract-text/17548409/pubmed\" id=\"17548409\" target=\"_blank\">",
"        17548409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore TA, &ldquo;Schizophrenia Treatment Guidelines in the United States,&rdquo;",
"      <i>",
"       Clin Schizophr Relat Psychoses",
"      </i>",
"      , 2011, 5(1):40-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/44/36550/abstract-text/21459738/pubmed\" id=\"21459738\" target=\"_blank\">",
"        21459738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10193 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-3C5F28D7A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_44_36550=[""].join("\n");
var outline_f35_44_36550=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210521\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210535\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210525\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210526\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10076328\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234244\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210508\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210507\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210533\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210511\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210496\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210531\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210500\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210518\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210512\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210503\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210513\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210495\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210510\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10193\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10193|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/21/39252?source=related_link\">",
"      Pipotiazine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_44_36551="Insulin regular: Pediatric drug information";
var content_f35_44_36551=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Insulin regular: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?8/45/8922?source=see_link\">",
"    see \"Insulin regular: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/37/1621?source=see_link\">",
"    see \"Insulin regular: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2105104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HumuLIN&reg; R;",
"     </li>",
"     <li>",
"      HumuLIN&reg; R U-500;",
"     </li>",
"     <li>",
"      NovoLIN&reg; R",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2104962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humulin&reg; R;",
"     </li>",
"     <li>",
"      Novolin&reg; ge Toronto",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2983813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiabetic Agent, Parenteral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hyperkalemia, Adjunctive Treatment Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Insulin, Short-Acting",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Neonates are extremely sensitive to the effects of insulin; initiate therapy at the lower end of infusion rate and monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Optimization of caloric intake while on parenteral nutrition:",
"     </b>",
"     Continuous I.V. infusion: 0.01-0.1 units/kg/",
"     <b>",
"      hour",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hyperkalemia:",
"     </b>",
"     Continuous I.V. infusion: 0.05-0.1 units/kg/",
"     <b>",
"      hour",
"     </b>",
"     in conjunction with a dextrose infusion has been used in seven neonates (&lt;28 weeks GA) (Malone, 1991).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F2983824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/45/8922?source=see_link\">",
"      see \"Insulin regular: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The general objective of insulin replacement therapy is to approximate the physiologic pattern of insulin secretion. This requires a basal level of insulin throughout the day, supplemented by additional insulin at mealtimes. Since combinations using different types of insulins are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component. The frequency of doses and monitoring must be individualized in consideration of the patient&rsquo;s ability to manage therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Type 1 diabetes mellitus:",
"     </b>",
"     Infants, Children, Adolescents, and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Multiple daily doses or continuous subcutaneous infusion guided by blood glucose monitoring are the standard of diabetes care. The daily doses presented are expressed as the",
"     <b>",
"      total units/kg/day of all insulin formulations combined",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Initial dose:",
"     </b>",
"     SubQ: 0.2-0.6 units/kg/day in divided doses. Conservative initial doses of 0.2-0.4 units/kg/day are often recommended to avoid the potential for hypoglycemia. Regular insulin may be the only insulin formulation used initially.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Division of daily insulin requirement (\"conventional therapy\"):",
"     </b>",
"     Generally, 50% to 75% of the daily insulin dose is given as an intermediate- or long-acting form of insulin (in 1-2 daily injections). The remaining portion of the 24-hour insulin requirement is divided and administered as either regular insulin or a rapid-acting form of insulin at the same time before breakfast and dinner.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Division of daily insulin requirement (\"intensive therapy\"):",
"     </b>",
"     Basal insulin delivery with 1 or 2 doses of intermediate- or long-acting insulin formulations superimposed with doses of rapid- or very rapid-acting insulin formulations 3 or more times daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Adjustment of dose:",
"     </b>",
"     Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Usual maintenance range:",
"     </b>",
"     0.5-1 unit/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents: May require &le;1.2 units/kg/day during growth spurts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Nonobese: 0.4-0.6 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Obese: 0.8-1.2 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Continuous SubQ insulin infusion (insulin pump):",
"     </b>",
"     A combination of a \"basal\" continuous insulin infusion rate with preprogrammed, premeal bolus doses which are patient controlled. When converting from multiple daily SubQ doses of maintenance insulin, it is advisable to reduce the basal rate to less than the equivalent of the total daily units of longer acting insulin (eg, NPH). Divide the total number of units by 24 to get the basal rate in units/hour. Do not include the total units of regular insulin or other rapid-acting insulin formulations in this calculation. The same premeal regular insulin dosage may be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Type 2 diabetes mellitus:",
"     </b>",
"     Augmentation therapy (patients for which diet, exercise, weight reduction, and oral hypoglycemic agents have not been adequate): Adults: SubQ: Initial dosage of 0.2 units/kg/day or 10 units/day of an intermediate- or long-acting insulin administered at bedtime has been recommended. As an alternative, regular insulin or rapid-acting insulin formulations administered before meals have also been used. Dosage must be carefully adjusted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Diabetic ketoacidosis: Note:",
"     </b>",
"     Patients newly diagnosed with IDDM presenting in DKA or patients with blood glucose levels &lt;800 mg/dL may be relatively \"sensitive\" to insulin and should receive loading and initial maintenance doses ~50% of those indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: Continuous I.V. infusion: 0.05-0.1 units/kg/",
"     <b>",
"      hour",
"     </b>",
"     (range: 0.05-0.2 units/kg/",
"     <b>",
"      hour",
"     </b>",
"     ) depending upon the rate of decrease of serum glucose (decreasing the serum glucose level too rapidly may lead to cerebral edema; optimum rate of decrease of serum glucose 80-100 mg/dL/hour). Continue infusion until acidosis clears (pH &gt;7.3 and HCO",
"     <sub>",
"      3",
"     </sub>",
"     &gt;25 mEq/L), not when the blood glucose normalizes. SubQ therapy may begin when the HCO",
"     <sub>",
"      3",
"     </sub>",
"     &gt;16 mEq/L, pH &gt;7.3, and/or anion gap &lt;16 mEq/L. Continue I.V. insulin infusion until the onset of the SubQ insulin dose (for regular insulin: 30-60 minutes).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: I.V.: Regular insulin 0.15 units/kg (~15-20 units) initially followed by an infusion of 0.1 units/kg/",
"     <b>",
"      hour",
"     </b>",
"     (~7 units/hour); increase infusion rate achieve glucose serum reduction of 50-70 mg/dL/hour. Decrease dose to 0.05-0.1 units/kg/",
"     <b>",
"      hour",
"     </b>",
"     once serum glucose reaches 250 mg/dL and ketoacidosis/acid-base abnormalities have resolved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hyperkalemia (after treatment with calcium and sodium bicarbonate):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: Dextrose 0.5-1 g/kg (using D",
"     <sub>",
"      25",
"     </sub>",
"     W or D",
"     <sub>",
"      50",
"     </sub>",
"     W) combined with regular insulin 1 unit for every 4-5 g dextrose; infuse over 2 hours",
"     <b>",
"      OR",
"     </b>",
"     as an alternative, dextrose 0.5-1 g/kg infused over 15-30 minutes followed by 0.1 unit/kg insulin SubQ or I.V.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 10 units regular insulin mixed with 25 g dextrose (50 mL D",
"     <sub>",
"      50",
"     </sub>",
"     W) given over 15-30 minutes (ACLS, 2005); alternatively, 50 mL D",
"     <sub>",
"      50",
"     </sub>",
"     W over 5 minutes followed by 10 units regular insulin I.V. push over seconds may be administered in the setting of imminent cardiac arrest. In patients with ongoing cardiac arrest (eg, PEA with presumed hyperkalemia), administration of D",
"     <sub>",
"      50",
"     </sub>",
"     W over &lt;5 minutes is routine. Effects on potassium are temporary. As appropriate, consider methods of enhancing potassium removal/excretion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Insulin requirements are reduced due to changes in insulin clearance or metabolism; no dosage adjustment provided in manufacturer&rsquo;s labeling; however, the following adjustments have been used by some clinicians (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer at 75% of recommended dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer at 50% of recommended dose and monitor glucose closely",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemodialysis: Because of a large molecular weight (6000 daltons), insulin is not significantly removed by either peritoneal or hemodialysis; supplemental dose is not necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peritoneal dialysis: Supplemental dose is not necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Continuous renal replacement therapy: Administer at 75% of recommended dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2104923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HumuLIN&reg; R: 100 units/mL (3 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NovoLIN&reg; R: 100 units/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HumuLIN&reg; R U-500: 500 units/mL (20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2104963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2983825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SubQ, I.M.: Administration is usually made into the subcutaneous fat of the thighs, arms, buttocks, or abdomen, with sites rotated; may be administered I.M. however, SubQ is the preferred route. When mixing regular insulin with other insulin preparations, regular insulin should be drawn into the syringe first; administer 30-60 minutes before meals. May be infused SubQ by external insulin pump; however, when used in an external pump, it is not recommended to be diluted with other solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Regular insulin is the preferred insulin formulation approved for I.V. administration (insulin aspart and insulin glulisine have been approved for I.V. administration in carefully controlled clinical settings with medical supervision and close monitoring of blood glucose as well as serum potassium); to minimize absorption of insulin to I.V. solution bag or tubing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If new tubing is",
"     <b>",
"      not",
"     </b>",
"     needed: Wait a minimum of 30 minutes between the preparation of the solution and the initiation of the infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If new tubing is needed: After receiving the insulin continuous infusion solution, the administration set should be attached to the I.V. container and the line should be flushed with the insulin solution, wait 30 minutes, then flush the line again with the insulin solution prior to initiating the infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Because of adsorption, the actual amount of insulin being administered could be substantially less than the apparent amount. Therefore, adjustment of the insulin drip rate should be based on the effect and not solely on the apparent insulin dose. Furthermore, the apparent I.V. infusion dose should not be used as the basis for determining the subsequent insulin dose upon discontinuing the insulin drip. Dosage adjustment requires continuous medical supervision.",
"    </p>",
"   </div>",
"   <div class=\"block uicn drugH1Div\" id=\"F14472662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. Infusion:",
"     </b>",
"     0.1 unit/mL",
"     <b>",
"      or",
"     </b>",
"     0.5 unit/mL",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     0.1 unit/mL, 0.5 unit/mL,",
"     <b>",
"      or",
"     </b>",
"     1 unit/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2104980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W and NS.",
"     <b>",
"      Note:",
"     </b>",
"     A universal sterile diluent, Sterile Diluent for Humalog&reg;, Humulin&reg; N, Humulin&reg; R, Humulin&reg; 70/30, and Humulin&reg; R U-500, is available from the manufacturer for SubQ administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alcohol (ethyl), amiodarone, ampicillin, ampicillin/sulbactam, aztreonam, caspofungin, cefazolin, cefepime, cefotetan, ceftazidime, dobutamine, doripenem, esmolol, famotidine, gentamicin, heparin, heparin with hydrocortisone sodium succinate, imipenem/cilastatin, indomethacin, magnesium sulfate, meperidine, meropenem, midazolam, milrinone, morphine, nitroglycerin, nitroprusside, oxytocin, pancuronium, pentobarbital, potassium chloride, propofol, sodium bicarbonate, tacrolimus, terbutaline, ticarcillin/clavulanate, tobramycin, vancomycin, vasopressin, vecuronium, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Dopamine, drotrecogin alfa, micafungin, nafcillin, nesiritide, ranitidine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Digoxin, diltiazem, doxapram, labetalol, levofloxacin, norepinephrine, pantoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Insulin NPH, metoclopramide.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Insulin aspart, insulin detemir, insulin glargine, insulin glulisine, insulin lispro, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Lidocaine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2983821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Regular insulin should only be used if clear. May be mixed in the same syringe with NPH insulin; draw regular insulin into syringe first.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Humulin&reg; R, Humulin&reg; R U-500: Store unopened vials in refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze; keep away from heat and sunlight. Once punctured (in use), vials may be stored in refrigerator between 2&deg;C and 8&deg;C (36&deg;F to 46&deg;F) or at room temperature &le;30&deg;C (&le;86&deg;F) for up to 31 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Novolin&reg; R: Store unopened vials in refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) until product expiration date or at room temperature &le;25&deg;C (&le;77&deg;F) for up to 42 days; do not freeze; keep away from heat and sunlight. Once punctured (in use), store vials at room temperature &le;25&deg;C (&le;77&deg;F) for up to 42 days (includes days stored at room temperature for unopened vials, if applicable); refrigeration of in use vials is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Continuous I.V. infusion: May be diluted in NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, or D",
"     <sub>",
"      10",
"     </sub>",
"     W; tubing should be flushed 30 minutes prior to administration to allow adsorption as time permits.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Humulin&reg; R: Stable for 48 hours at room temperature or for 48 hours under refrigeration followed by 48 hours at room temperature when diluted in NS at a final concentration of 0.1-1 unit/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Novolin&reg; R: Stable for 24 hours at room temperature when diluted in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W or D",
"     <sub>",
"      10",
"     </sub>",
"     W at a final concentration of 0.05-1 unit/mL",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2983814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of insulin-dependent diabetes mellitus, also noninsulin-dependent diabetes mellitus unresponsive to treatment with diet and/or oral hypoglycemics; to assure proper utilization of glucose and reduce glucosuria in nondiabetic patients receiving parenteral nutrition (glucosuria cannot be adequately controlled with infusion rate adjustments or requires assistance in achieving optimal caloric intakes); treatment of hyperkalemia (use with glucose to shift potassium into cells to lower serum potassium levels)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2104961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       HumuLIN&reg; R may be confused with HumaLOG&reg;, Humira&reg;, HumuLIN&reg; 70/30, HumuLIN&reg; N, NovoLIN&reg; 70/30, NovoLIN&reg; R, NovoLOG&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       NovoLIN&reg; R may be confused with HumuLIN&reg; R, NovoLIN&reg; 70/30, NovoLIN&reg; N, NovoLOG&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"       <b>",
"        <i>",
"         Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.",
"        </i>",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Concentrated solutions (eg, U-500) should not be available in patient care areas. U-500 regular insulin should be stored, dispensed, and administered separately from U-100 regular insulin. For patients who receive U-500 insulin in the hospital setting, highlighting the strength prominently on the patient&rsquo;s medical chart and medication record may help to reduce dispensing errors.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F2104971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Primarily symptoms of hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Pallor, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, hypothermia, loss of consciousness, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Redness, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Hunger, nausea, numbness of mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Atrophy or hypertrophy of SubQ fat tissue; edema, itching, pain or warmth at injection site; stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Transient presbyopia or blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, local and/or systemic hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2983816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to regular insulin or any component; hypoglycemia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2983931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use with caution and adjust dosage in patients with renal impairment; use with caution and monitor closely in patient with hepatic impairment. While regular insulin is the preferred formulation for I.V. administration, both insulin aspart and insulin glulisine have been approved for I.V. use in selected clinical situations with close medical supervision and monitoring of serum potassium.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2983817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypoglycemia is the most common adverse effect of insulin. The timing of hypoglycemia differs among various insulin formulations. Any change of insulin should be made cautiously; changing manufacturers, type, and/or method of manufacture may result in the need for a change of dosage. Hypoglycemia may result from increased work or exercise without eating; use of long-acting insulin preparations (insulin glargine, Ultralente&reg;) with regular insulin may delay recovery from hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F2104975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2104974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Insulin may enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Insulin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Insulin may enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2983820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use caution with chromium, garlic, gymnema (may increase hypoglycemia).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F14079518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2105111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Minimal amounts of endogenous insulin cross the placenta. Exogenous insulin bound to anti-insulin antibodies has been detected in cord blood. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is &gt;1% above the normal range. Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28-32 weeks of gestation. Following delivery, insulin requirements decrease rapidly. Diabetes can also be associated with adverse effects in the mother. Poorly treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the fetus and the mother. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2983826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urine sugar and acetone, serum glucose, electrolytes, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     , lipid profile",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DKA: Arterial blood gases (initial), venous pH, CBC with differential, urinalysis, serum glucose (baseline and every hour until reaches 250 mg/dL), BUN, creatinine, electrolytes, anion gap, I&amp;O",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyperkalemia: Serum potassium and glucose must be closely monitored to avoid hypoglycemia and/or hypokalemia.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2983827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucose, fasting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 30-90 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 70-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommendations for glycemic control with type 1 diabetes:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;6 years: &le;8.5% and &ge;7.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-12 years: &lt;8%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     13-19 years: &lt;7.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: &lt;7%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plasma glucose*:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Preprandial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;6 years: 90-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-12 years: 90-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     13 years to Adults: 90-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bedtime and overnight:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;6 years: 110-200 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-12 years: 100-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     13-19 years: 90-150 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peak postprandial** : Adults: &lt;180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     *Plasma glucose concentrations are generally 10% to 15% higher than those in whole blood",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     **Peak postprandial plasma glucose is measured 1-2 hours after a meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Criteria for diagnosis of DKA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum glucose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: &gt;200 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: &gt;250 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Arterial pH:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: &lt;7.3",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: &lt;7-7.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bicarbonate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: &lt;15 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: &lt;10-15 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate ketonuria or ketonemia",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2983822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Insulin facilitates entry of glucose into muscle, adipose, and other tissues via hexose transporters, including GLUT4. Insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Target organs for insulin include the liver, skeletal muscle, and adipose tissue. Within the liver, insulin stimulates hepatic glycogen synthesis through the activation of the enzymes hexokinase, phosphofructokinase, and glycogen synthase as well as the inhibition of glucose-6 phosphatase. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes. Insulin also directly inhibits the hydrolysis of triglycerides.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either",
"     <i>",
"      E. coli",
"     </i>",
"     or",
"     <i>",
"      Saccharomyces cerevisiae",
"     </i>",
"     . Insulins are categorized based on promptness and duration of effect, including rapid-, short-, intermediate-, and long-acting insulins. Regular insulin is considered a &ldquo;short-acting&rdquo; insulin.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F2983932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Onset and duration of hypoglycemic effects depend upon the route of administration (adsorption and onset of action are more rapid after deeper I.M. injections than after SubQ), site of injection (onset and duration are progressively slower with SubQ injection into the abdomen, arm, buttock, or thigh respectively), volume and concentration of injection, and the preparation administered; local heat and massage also increase the rate of absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Approximately 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 1-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 6-10 hours (may increase with dose)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2983823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.26-0.36 L/kg",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     Half-life: SubQ: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F2983828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/37/1621?source=see_link\">",
"      see \"Insulin regular: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new medication during therapy unless approved by healthcare provider. This medication is used to control diabetes; it is not a cure. It is imperative to follow other components of prescribed treatment (eg, diet and exercise regimen). Take exactly as directed. Do not change dose or discontinue unless advised by healthcare provider. If you experience hypoglycemic reaction, contact healthcare provider immediately. Always carry quick source of sugar with you. Monitor glucose levels as directed by healthcare provider. Report adverse side effects, including chest pain or palpitations; persistent fatigue, confusion, headache; skin rash or redness; numbness of mouth, lips, or tongue; muscle weakness or tremors; vision changes; respiratory difficulty; or nausea, vomiting, or flu-like symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F2983829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     In mild diabetic ketoacidosis or unusual circumstances, for patients without I.V. access, SubQ or I.M. regular insulin has been used. Doses are similar to the doses recommended for bolus and the hourly infusion (total dose administered once per hour). If volume depletion and secondary sympathetic activation decrease local perfusion, insulin absorption may be inconsistent. For this reason, many clinicians do not recommend this approach.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 112(24 Suppl): 1-211.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, \"Standards of Medical Care in Diabetes,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2007, 30(Suppl 1):4-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/44/36551/abstract-text/17192377 /pubmed\" id=\"17192377 \" target=\"_blank\">",
"        17192377",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practices (ISMP), \"Standard Concentrations of Neonatal Drug Infusions,\"",
"      <i>",
"       ISMP",
"      </i>",
"      , 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malone TA, \"Glucose and Insulin Versus Cation-Exchange Resin for the Treatment of Hyperkalemia in Very Low Birth Weight Infants,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1991, 118(1):121-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/44/36551/abstract-text/1986079/pubmed\" id=\"1986079\" target=\"_blank\">",
"        1986079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, \"Standardizing I.V. Infusion Concentrations: National Survey Results,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/44/36551/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simeon PS, Geffner ME, Levin SR, et al, \"Continuous Insulin Infusions in Neonates: Pharmacologic Availability of Insulin in Intravenous Solutions,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 124(5 Pt 1):818-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/44/36551/abstract-text/8176576/pubmed\" id=\"8176576\" target=\"_blank\">",
"        8176576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12880 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-83.177.194.223-190351C039-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_44_36551=[""].join("\n");
var outline_f35_44_36551=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2105104\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104962\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983813\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443748\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983824\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104923\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104963\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983825\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472662\">",
"      Usual Infusion Concentrations: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472661\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104980\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983821\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983814\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104961\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104971\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983816\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983931\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983817\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104975\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104974\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983820\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079518\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2105111\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983826\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983827\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983822\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983932\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983823\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983828\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983829\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12880\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12880|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/45/8922?source=related_link\">",
"      Insulin regular: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/37/1621?source=related_link\">",
"      Insulin regular: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_44_36552="Carcinoid lung low power";
var content_f35_44_36552=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Carcinoid tumor of the lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph showing a carcinoid tumor of the lung with a characteristic neuroendocrine growth pattern.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_44_36552=[""].join("\n");
var outline_f35_44_36552=null;
var title_f35_44_36553="Polio and infectious diseases of the anterior horn";
var content_f35_44_36553=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Polio and infectious diseases of the anterior horn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/44/36553/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/44/36553/contributors\">",
"     Zachary Simmons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/44/36553/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/44/36553/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/44/36553/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/44/36553/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/44/36553/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although polio no longer poses the public health threat in the United States that it once did, areas of endemic wild-type poliovirus still exist in other areas of the world. An understanding of this virus and other enteroviruses is important in the evaluation of the patient with acute flaccid paralysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ENTEROVIRUS CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human enteroviruses contain a single-stranded RNA genome, and are divided into five species: poliovirus and human enteroviruses A, B, C, and D.",
"   </p>",
"   <p>",
"    There are 64 human serotypes of enteroviruses. The three poliovirus serotypes are conveniently named types 1, 2, and 3. All produce motor neuron disease, although most paralytic disease was caused by poliovirus type 1 in the prevaccination era. The non-polio enteroviruses include coxsackieviruses A and B and various echoviruses and enteroviruses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/26/41383?source=see_link\">",
"     \"Epidemiology, pathogenesis, treatment, and prevention of enterovirus and parechovirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     POLIOVIRUS AND POLIOMYELITIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polio epidemics that occurred in the first half of the 20th century in the United States were, ironically, a result of improved sanitation. Prior to 1900 in the United States, polio was endemic. Most infants were infected with poliovirus before age six months. While some developed infantile paralysis, many were protected by maternal antibodies and had inapparent infections, resulting in widespread immunity in American children. Improved sanitation led to many less infants being exposed to poliovirus, creating a large pool of susceptible individuals. When exposure occurred later and the individuals were not protected by maternal antibodies, there were polio epidemics.",
"   </p>",
"   <p>",
"    The first major United States outbreak of polio was in 1916, during which 6000 people died and 27,000 were paralyzed. Epidemics continued to occur every few years and to grow. In 1952, there were 57,000 cases of polio [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Similarly, polio was endemic in less industrialized areas of the world well into the 20th century. As sanitation and hygiene improved in these countries, they too began to experience epidemics of poliomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poliovirus is transmitted by oral-fecal contact. During epidemics, it also may be transmitted by pharyngeal spread [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/5\">",
"     5",
"    </a>",
"    ]. Entry is via the oral route, during which the virus infects cells of the mouth, nose, and throat. Ninety to 95 percent of poliovirus infections are asymptomatic. There is an incubation period of 7 to 14 days, during which the virus undergoes primary replication in the lymphatic tissues of the GI tract. An asymptomatic primary (minor) transient viremia occurs, with spread of virus to the systemic reticuloendothelial tissue.",
"   </p>",
"   <p>",
"    In 4 to 8 percent of individuals, a second major viremia occurs, causing symptoms of the \"minor illness\" (abortive polio), which resembles the usual viral infection, including headache, sore throat, fever, nausea, vomiting, malaise, and fatigue. In a fraction of those with major viremia and abortive polio, involvement of the central nervous system then occurs, usually after a symptom-free interval of a few days. This usually is signaled by signs and symptoms of meningitis, including neck stiffness, headache, fever, and vomiting. In some of these patients, the poliovirus then causes selective destruction of motor neurons, characterized by severe back, neck, and muscle pain, and the development of motor weakness. This paralysis occurs in only about 0.1 percent of all poliovirus infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of spread of poliovirus to the central nervous system is not well understood. It may occur by direct passage of the virus from blood by crossing the blood-brain barrier, or may occur by retrograde axonal transport from muscle to spinal cord and brain.",
"   </p>",
"   <p>",
"    After invading the central nervous system, the virus uncoats, viral replication occurs, and the motor neuron dies, leading to paralysis of muscle fibers supplied by this motor neuron. Spread of the virus to neighboring motor neurons may occur laterally, independent of axonal transport, or by transneuronal spread, in a retrograde transport dependent fashion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/6\">",
"     6",
"    </a>",
"    ]. Other neurons can be infected as well, producing brainstem encephalitis and respiratory insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weakness may vary from one muscle or group of muscles, to quadriplegia, and respiratory failure. Tone is reduced, nearly always in an asymmetric manner. Proximal muscles usually are affected more than distal muscles, and legs more commonly than arms. Reflexes are decreased or absent. The sensory examination is normal.",
"   </p>",
"   <p>",
"    Weakness typically worsens over two to three days, although sometimes worsening can progress for up to a week. Bulbar involvement occurs in 5 to 35 percent of patients, producing dysphagia, dysarthria, and difficulty handling secretions. There may be encephalitis, usually in infancy. Respiratory insufficiency may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/1,8\">",
"     1,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Evaluation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of poliomyelitis is suspected based on the clinical presentation and cerebrospinal fluid findings.",
"   </p>",
"   <p>",
"    The cerebrospinal fluid shows a pleocytosis as in other types of aseptic meningitis, initially characterized by polymorphonuclear leukocytes, followed by a shift to lymphocytes. The cerebrospinal fluid protein is usually elevated.",
"   </p>",
"   <p>",
"    The diagnosis can be confirmed by virus isolation. Poliovirus can be isolated from throat secretions in the first week of illness, and from feces for several weeks. It rarely can be isolated from cerebrospinal fluid. The diagnosis can also be confirmed by polymerase chain reaction amplification of poliovirus RNA from cerebrospinal fluid or serologically, by comparing viral titers in acute and convalescent sera [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/1,5,7,8\">",
"     1,5,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electrodiagnostic investigations reveal normal sensory nerve studies. Motor nerve studies show normal to mildly slowed conduction velocities and low to normal amplitudes. Needle examination acutely demonstrates only decreased or absent recruitment, but eventually demonstrates fibrillation potentials, positive sharp waves, and occasionally fasciculation potentials in affected muscles. A summary of the recommended evaluation of the patient with acute flaccid paralysis is provided in the Table (",
"    <a class=\"graphic graphic_table graphicRef73307 \" href=\"mobipreview.htm?20/50/21291\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of acute flaccid paralysis is summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef71165 \" href=\"mobipreview.htm?35/20/36171\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enteroviruses other than wild-type polio must be considered, particularly in the current era in which polio has been eradicated in most countries. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Nonpolio enteroviruses causing acute flaccid paralysis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      West Nile virus, a mosquito-borne flavivirus, can produce acute flaccid paralysis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/47/22264?source=see_link\">",
"       \"Clinical manifestations and diagnosis of West Nile virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other infections, such as diphtheria and botulism, may also produce acute flaccid paralysis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/38/29287?source=see_link\">",
"       \"Epidemiology, pathophysiology and clinical manifestations of diphtheria\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/36/37448?source=see_link\">",
"       \"Botulism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Disease at other levels of the neuraxis must also be considered. Spinal cord disorders such as transverse myelitis, cord infarction, and cord compression can produce weakness. Upper motor neuron findings are typically produced by these conditions, but may be absent initially. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32426?source=see_link\">",
"       \"Disorders affecting the spinal cord\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Guillain-Barr&eacute; syndrome should be considered as well, and usually can be distinguished from poliovirus by its symmetry, the lack of preceding aseptic meningitis, the absence of a cerebrospinal fluid pleocytosis, and the presence of multifocal demyelination on electrodiagnostic testing. Of course, the electrodiagnostic findings are less helpful early in the course of Guillain-Barr&eacute; syndrome, when demyelinating findings may not yet have developed, or in the case of axonal forms of Guillain-Barr&eacute; syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/22/5481?source=see_link\">",
"       \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27705?source=see_link\">",
"       \"Overview of Guillain-Barr&eacute; syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Peripheral motor neuropathy may be a feature of acute intermittent porphyria. Muscle weakness often begins proximally in the legs but may involve the arms or the distal extremities. Motor neuropathy may also involve the cranial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      phrenic nerves leading to bulbar paralysis and respiratory impairment, and may result in death if undetected. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10439?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute intermittent porphyria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mononeuritis multiplex is typically painful, associated with sensory as well as motor symptoms and signs, and with weakness in the distribution of specific peripheral nerves. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22423?source=see_link\">",
"       \"Clinical manifestations of vasculitic neuropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Disorders of neuromuscular transmission may produce acute flaccid paralysis. These disorders are typically symmetric, associated with normal cerebrospinal fluid, and characterized by abnormal findings on repetitive nerve stimulation. They are usually not associated with a prodromal illness. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=see_link\">",
"       \"Clinical manifestations of myasthenia gravis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/9/35992?source=see_link\">",
"       \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/45/41688?source=see_link\">",
"       \"Overview of neuromuscular junction toxins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inflammatory myopathy usually has a less abrupt onset, no prodromal illness, a high serum creatine kinase (CK) level, and symmetry. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=see_link\">",
"       \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15735?source=see_link\">",
"       \"Clinical manifestations and diagnosis of inclusion body myositis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with rhabdomyolysis may experience rapidly developing quadriparesis, but in association with severe muscle pain, symmetry, a dramatically elevated serum CK level, myoglobinuria, and normal cerebrospinal fluid. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=see_link\">",
"       \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    From a practical clinical perspective, the illnesses which most resemble poliomyelitis are other enterovirus infections, West Nile Virus, and Guillain-Barr&eacute; syndrome. It is particularly important to identify Guillain-Barr&eacute; syndrome when present, and to distinguish it from a viral disorder of the motor neurons, because it is treated with interventions (intravenous immune globulin or plasma exchange) that should be instituted early in the clinical course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment, course, and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of poliomyelitis is supportive, including pain relief and physical therapy. Respiratory failure may develop, requiring mechanical ventilation. Patients with bulbar involvement require close monitoring of cardiovascular status because of the association with blood pressure fluctuations, circulatory collapse, and autonomic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/1,5,8,9\">",
"     1,5,8,9",
"    </a>",
"    ]. Such patients may require intubation for airway protection.",
"   </p>",
"   <p>",
"    Pleconaril has shown mixed results in treating enteroviral infections.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study found that 12 of 16 patients with chronic enteroviral meningoencephalitis improved clinically with pleconaril administration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two randomized controlled trials that enrolled 240 patients with confirmed enteroviral meningitis did not demonstrate overall clinical benefit for pleconaril treatment compared with placebo. However, a post hoc subgroup analysis found that pleconaril treatment was associated with more rapid headache resolution in patients with moderate or severe nausea and in those with severe or very severe headache [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the role of antiviral therapy in the treatment of enterovirus-related acute flaccid paralysis remains uncertain at this time. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/26/41383?source=see_link\">",
"     \"Epidemiology, pathogenesis, treatment, and prevention of enterovirus and parechovirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    About two-thirds of patients with acute flaccid paralysis do not regain full strength. The more severe the acute weakness, the greater the chance of residual deficits. Bulbar sequelae are rare. The mortality was 5 to 10 percent in the era of epidemics, and approached 50 percent for those with bulbar involvement because of cardiovascular and respiratory complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/1,5,8,9\">",
"     1,5,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Post-polio syndrome may occur many years after the acute episode, and has been defined as the \"onset of functional deterioration after a prolonged period of stability\" in patients with a history of polio [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/9\">",
"     9",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/45/5849?source=see_link\">",
"     \"Post-polio syndrome\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Polio has long-lasting effects on its victims, whether or not they meet criteria for post-polio syndrome. A study found that secondary conditions common among polio survivors include new muscle weakness, chronic pain, contractures, depression, fatigue, sleep problems, and a host of other symptoms and signs, all of which may have a negative impact on life satisfaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Polio vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because there are no effective treatments to restore motor neuron function after paralytic polio, prevention has been a mainstay of clinical and research efforts. Jonas Salk created the inactivated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/58/35749?source=see_link\">",
"     poliovirus vaccine",
"    </a>",
"    (IPV), using killed virus in 1952. Vaccination of 1.8 million grade school children at 217 test sites in 44 states was carried out in 1954, and the vaccine was found to be 80 to 90 percent effective in preventing polio [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]. Routine use of IPV began in 1956 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/9\">",
"     9",
"    </a>",
"    ]. The Sabin oral poliovirus vaccine (OPV), using live attenuated virus, proved successful in 1960, and replaced the Salk vaccine in 1962 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/9,14\">",
"     9,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In areas of the world where polio is endemic, primary immunization is still performed with Sabin OPV. But, because it causes polio in one out of 2.5 million cases, it has been replaced by the Salk IPV in countries without polio, including the United States and most of Europe.",
"   </p>",
"   <p>",
"    Polio vaccination is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/52/17223?source=see_link\">",
"     \"Poliovirus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Paralytic disease associated with vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The OPV accounts for some cases of acute flaccid paralysis in the form of either vaccine-associated paralytic poliomyelitis (VAPP) or vaccine-derived poliomyelitis (VDP).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaccine-associated paralytic poliomyelitis is a rare effect, occurring in about one person per 2.5 million doses, but more common in immunodeficient patients, particularly those with B-cell immunodeficiencies and hypogammaglobulinemia. It usually occurs after the first dose of OPV, and may affect the individual vaccinated or a close contact of that person. The mechanism appears to be mutation of the vaccine virus to a neurovirulent form. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/52/17223?source=see_link&amp;anchor=H9#H9\">",
"       \"Poliovirus vaccination\", section on 'Adverse effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vaccine-derived poliomyelitis is a term used to refer to outbreaks of acute flaccid paralysis caused by circulating poliovirus strains derived from one of the three Sabin poliovirus strains in OPV. Outbreaks of vaccine-derived poliomyelitis occur when OPV is used in regions with low immunization rates, permitting vaccine-derived poliovirus to circulate for long periods of time, to mutate, and to acquire biologic properties similar to those of naturally occurring wild-type polioviruses. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/52/17223?source=see_link&amp;anchor=H9#H9\">",
"       \"Poliovirus vaccination\", section on 'Adverse effects'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Polio eradication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccination against polio has had a profound effect. The last case of endemic, naturally occurring poliomyelitis in the United States was reported in 1979 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. The last such case in the Western Hemisphere was reported in Peru in 1991. The only known wild poliovirus infections in the Americas after 1991 were imported cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The basis of the Global Polio Eradication Initiative, initiated in 1988, has been immunization and surveillance (",
"    <a class=\"graphic graphic_table graphicRef57046 \" href=\"mobipreview.htm?3/33/3611\">",
"     table 3",
"    </a>",
"    ). Progress is tracked through surveillance of acute flaccid paralysis cases and testing of linked stool specimens for polioviruses, with additional testing of sewage in selected areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/17\">",
"     17",
"    </a>",
"    ]. In areas in which surveillance systems detect at least one case of acute flaccid paralysis per 100,000 persons aged &lt;15 years, stool samples are collected and analyzed, and the data are used to identify locations where wild polioviruses or vaccine-derived polioviruses are circulating [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results have been dramatic. In 1988, polio was endemic in more than 125 countries, and paralyzed at least 350,000 children per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/19\">",
"     19",
"    </a>",
"    ]. By 2003, the number of cases of acute flaccid paralysis due to poliovirus was reduced to 784. By 2010, there remained only four countries in which endemic wild poliovirus transmission had never been interrupted: Afghanistan, India, Nigeria, and Pakistan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/20\">",
"     20",
"    </a>",
"    ]. In early 2012, India reported for the first time that no new cases of wild poliovirus were recorded during the previous 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/21\">",
"     21",
"    </a>",
"    ]. The number of polio cases worldwide declined from 1352 in 2010 to 650 in 2011 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wild type 2 poliovirus has not been isolated globally since 1999, and so may have already been eradicated.",
"   </p>",
"   <p>",
"    Despite this progress, the need for continued vigilance is clear.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 2010, a large outbreak of wild type 1 poliovirus occurred in a region certified as polio-free since 2002 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/20\">",
"       20",
"      </a>",
"      ]. Most of the cases were in Tajikistan (n = 458), and others occurred in Kazakhstan, Russia, and Turkmenistan.",
"     </li>",
"     <li>",
"      An outbreak of wild type 1 poliovirus, the first in 10 years, occurred in the Republic of the Congo from September 2010 to February 2011 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These outbreaks highlight the risk for wild poliovirus reintroduction due to a combination of international travel, health systems with limited resources, areas of low oral poliovirus coverage, and delays in recognizing and testing cases of acute flaccid paralysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NONPOLIO ENTEROVIRUSES CAUSING ACUTE FLACCID PARALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like poliovirus, nonpolio enteroviruses usually produce infections that are clinically inapparent, but they may invade the central nervous system. Although aseptic meningitis is the most common central nervous system manifestation of enteroviruses (followed by encephalitis), acute flaccid paralysis has been found to be caused by coxsackieviruses and echoviruses in the Soviet Union, Scotland, and South Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/19,24-30\">",
"     19,24-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The paralysis caused by coxsackievirus and echovirus infections is usually milder than that seen in association with polioviruses. Permanent paralysis is uncommon after coxsackievirus and echovirus infections. Usually there is resolution of the deficit by 60 days after onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=see_link\">",
"     \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/26/41383?source=see_link\">",
"     \"Epidemiology, pathogenesis, treatment, and prevention of enterovirus and parechovirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other enteroviruses have been implicated as well. Enterovirus 71 (EV71), first identified in California in 1969, has a long history of producing acute flaccid paralysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/15,31-33\">",
"     15,31-33",
"    </a>",
"    ]. During an epidemic of EV71 infection in Bulgaria in 1975, a poliomyelitis-like syndrome developed in 7.4 percent of those infected, and bulbar weakness developed in 9.6 percent. Young children were the most severely affected.",
"   </p>",
"   <p>",
"    Histopathologically, these patients were found to have lesions typical of acute anterior poliomyelitis and bulbar polioencephalitis, predominantly in the medulla and spinal cord [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. In 1978, 1550 cases of EV71 infections with central nervous system involvement were identified in Hungary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/36\">",
"     36",
"    </a>",
"    ]. Thirteen of these were cases of acute flaccid paralysis, all in children between 8 and 36 months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enterovirus 70 (EV70) has been widely reported to produce acute flaccid paralysis in association with acute hemorrhagic conjunctivitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/7,37-40\">",
"     7,37-40",
"    </a>",
"    ]. Acute hemorrhagic conjunctivitis first occurred in epidemic form in Ghana in 1963. There were subsequently a number of epidemics and pandemics in Africa, Asia, and Europe, affecting tens of millions of individuals. One in 10,000 to 15,000 of these patients with acute hemorrhagic conjunctivitis developed acute flaccid paralysis, mostly older teens and adults. As with poliomyelitis, most of these patients with acute flaccid paralysis had a cerebrospinal fluid pleocytosis and elevated cerebrospinal fluid protein level. Diagnosis was made by isolation of the virus from the eyes early in the illness, or by a rise in antibody titers between paired sera [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/7,37-40\">",
"     7,37-40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Epidemiology subsequent to polio eradication efforts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of acute flaccid paralysis has changed dramatically since the introduction of mass vaccination programs for polio eradication worldwide. With the possible exception of those cases associated with acute hemorrhagic conjunctivitis, cases of acute flaccid paralysis due to nonpolio enteroviruses were relatively rare compared with poliovirus-related cases in the prevaccination era. This is no longer the case.",
"   </p>",
"   <p>",
"    Surveillance studies of acute flaccid paralysis conducted by the World Health Organization (WHO) have been particularly enlightening in this regard.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Brazil, where the last cases of acute flaccid paralysis due to wild poliovirus occurred in 1989, a number of children were found to have acute flaccid paralysis due to EV71 from 1988 to 1990 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/41,42\">",
"       41,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acute flaccid paralysis occurred in children during epidemics of hand, foot, and mouth disease due to EV71 in Malaysia in 1997 and in Tunisia in 1998 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/19,43\">",
"       19,43",
"      </a>",
"      ]. Between 1992 and 2002, 1063 stool specimens were obtained from 641 patients with acute flaccid paralysis in Malaysia. Of 107 enteroviruses isolated, 36 were polioviruses, while the others were non-polio enteroviruses, including coxsackie B viruses, various echoviruses, EV71, and other enteroviruses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/44\">",
"       44",
"      </a>",
"      ]. Stool samples collected from all patients with acute flaccid paralysis in Tunisia from 1992 through 2003 identified Sabin-like strains of viruses or nonpolio enteroviruses including echoviruses and coxsackieviruses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      EV71 continues to be implicated in cases of acute flaccid paralysis in Asia-Pacific countries, and has been termed &ldquo;the new polio&rdquo; by some [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occasional sporadic cases of acute flaccid paralysis due to nonpolio enteroviruses continue to appear as well. A report of coxsackievirus producing acute flaccid paralysis in a young child was described in Japan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/46\">",
"     46",
"    </a>",
"    ]. Acute flaccid paralysis in a three-year-old boy due to an echovirus was described in New Zealand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/47\">",
"     47",
"    </a>",
"    ]. Interestingly, adenoviruses have also been implicated in a small number of cases of acute flaccid paralysis in a study from South America, although the adenoviruses appeared to cause less than 2 percent of such cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     VIRUSES AND AMYOTROPHIC LATERAL SCLEROSIS SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between certain viruses (HIV-1, HTLV-1, and enteroviruses) and amyotrophic lateral sclerosis (ALS) or an ALS-like syndrome is under investigation. Both HIV-1 and HTLV-1 have been implicated in some ALS-like syndromes, but the clinical presentations are atypical for ALS. In contrast, studies of postmortem central nervous system tissue and of cerebrospinal fluid from patients with unequivocal clinical evidence of ALS have revealed enterovirus more frequently than in controls, but the contribution of such viruses to ALS pathogenesis remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     HIV-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although HIV-1 is not a neurotropic virus, the identification of a clinical syndrome resembling amyotrophic lateral sclerosis (ALS) in patients who are seropositive for HIV-1 has led to a search for a causal connection between the virus and the clinical syndrome. Individuals with concurrent ALS and HIV-1 infections are relatively uncommon. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40280?source=see_link\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Virtually all data regarding the association of HIV-1 infection with an ALS-like syndrome comes from case reports, except for one small series of six patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/49\">",
"     49",
"    </a>",
"    ]. An excellent summary of 19 cases from the literature and two additional patients demonstrates that many of these patients do not resemble the typical ALS patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients met El Escorial criteria for clinically possible or probable, but not clinically definite, ALS, and many demonstrated only lower motor neuron disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16938?source=see_link\">",
"       \"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The average age at onset of neurologic symptoms was 35 years, considerably younger than that seen in sporadic ALS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40280?source=see_link\">",
"       \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The rate of progression of the disease was faster than usual for ALS.",
"     </li>",
"     <li>",
"      Autopsy studies of three patients demonstrated that they did not have typical pathological findings of ALS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/50,51\">",
"       50,51",
"      </a>",
"      ], which is characterized by motor neuron degeneration and death with gliosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23450?source=see_link&amp;anchor=H8#H8\">",
"       \"Epidemiology and pathogenesis of amyotrophic lateral sclerosis\", section on 'Pathology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All three patients had pathologic findings outside of the spinal cord motor neuron pool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/50\">",
"     50",
"    </a>",
"    ]. One patient demonstrated myelopathy, fiber loss from the ventral roots, demyelination involving the intramuscular twigs of peripheral nerves, and myopathic abnormalities within some muscles, but no loss of cortical or spinal motor neurons. Another autopsy demonstrated AIDS encephalopathy, vacuolar myelopathy, and motor and sensory neuronal loss, all of which are pathologic features known to accompany HIV-1 infection. The third showed motor neuron atrophy and sensory neuropathy.",
"   </p>",
"   <p>",
"    An example is illustrative of the \"atypical\" nature of ALS in these individuals: One reported patient demonstrated rapidly progressive but symmetric weakness over three months, abnormalities on MRI, a mild cerebrospinal fluid pleocytosis, and a cerebrospinal fluid protein level of 134",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    He improved with anti-HIV treatment and his MRI normalized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with HIV-1 and ALS-like syndrome, the response to anti-HIV treatment has varied, with some individuals showing neurologic improvement and others not responding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/50\">",
"     50",
"    </a>",
"    ]. We have cared for two patients with HIV-1 infection and clinical features of classic ALS. Both patients had inexorable progression of neurologic dysfunction despite nondetectable levels of HIV-1 RNA.",
"   </p>",
"   <p>",
"    Because HIV is a treatable infection, patients with possible ALS and an atypical presentation should be tested for HIV status as part of their workup. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16938?source=see_link\">",
"     \"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Those patients with HIV-1 infection and features of motor neuron disease (whether typical or atypical for ALS) should be treated aggressively for their HIV infection. However, it is important for patients and practitioners to realize that HIV infection and ALS may occur together as a coincidence. In addition, there may be no neurologic stabilization or improvement despite \"successful\" treatment of the HIV infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22808?source=see_link\">",
"     \"Acute and early HIV infection: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A patient with HIV infection has been reported with the syndrome of brachial amyotrophic diplegia consisting of bilateral upper extremity weakness without having bulbar dysfunction, upper motor neuron signs, or sensory loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/53\">",
"     53",
"    </a>",
"    ]. This syndrome is often considered a manifestation of motor neuron disease. Treatment of HIV infection in this patient resulted in an undetectable viral load. The weakness progressed, and then appeared to stabilize. What, if any, causal relationship exists between the HIV infection and the neurologic picture in this particular individual remains unclear. It should be noted that this patient was diabetic, and in addition, was treated with a course of intravenous immune globulin without improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     HTLV-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human T-cell lymphotropic virus type 1 (HTLV-1) is a retrovirus which may produce several clinical neurologic manifestations. The usual manifestation is a slowly progressive, spastic paraparesis known as HTLV-1-associated",
"    <span class=\"nowrap\">",
"     myelopathy/tropical",
"    </span>",
"    spastic paraparesis",
"    <span class=\"nowrap\">",
"     (HAM/TSP).",
"    </span>",
"    Peripheral neuropathy occurs in up to 25 percent of such patients. In addition, HTLV-1 also may cause inflammatory myopathy, without or with spastic paraparesis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32426?source=see_link&amp;anchor=H10#H10\">",
"     \"Disorders affecting the spinal cord\", section on 'HTLV-1 myelopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40808?source=see_link\">",
"     \"Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, HTLV-1 infection is associated with an ALS-like syndrome sometimes called pseudo-ALS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Most commonly reported in blacks and in the Japanese, patients with pseudo-ALS have lower and upper motor neuron involvement, with a mean age of onset over 60 years. In contrast to typical sporadic ALS, there is a female preponderance. The initial presentation usually is that of gait dysfunction. Urinary frequency and incontinence are common, as are sensory disturbances, including numb, burning feet and tightness about the waist.",
"   </p>",
"   <p>",
"    The examination reveals muscle atrophy and fasciculations, usually involving small hand muscles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/54\">",
"     54",
"    </a>",
"    ]. Some patients have tongue atrophy and fasciculations. Electrodiagnostic findings resemble those of ALS. Consistent with the electrodiagnostic findings, muscle biopsies demonstrate denervation. An autopsy study of one patient revealed gliosis and CD8+ inflammatory cells in the anterior horns, with moderate anterior horn cell loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The course is a more slowly progressive one than typical ALS. Diagnosis is via detection of HTLV-1 DNA in peripheral blood or cerebrospinal fluid lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/54\">",
"     54",
"    </a>",
"    ]. Because of the more favorable prognosis of pseudo-ALS, it is helpful to identify such patients. Thus, patients with slowly progressive ALS who have prominent upper motor neuron signs should have HTLV-1 status checked as a part of the diagnostic evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31632106\">",
"    <span class=\"h2\">",
"     Enteroviruses and ALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on ability of enteroviruses to kill motor neurons and produce the polio-like syndrome of acute flaccid paralysis, there has been considerable investigation into whether motor neuron death in amyotrophic lateral sclerosis (ALS) is linked to enteroviruses. The evidence has been conflicting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23450?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology and pathogenesis of amyotrophic lateral sclerosis\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies support a link between enteroviruses and ALS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, enteroviral sequences related to coxsackie B virus sequences were detected in spinal cord tissue from 8 of 11 patients with sporadic motor neuron disease and one of two patients with familial motor neuron disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two other postmortem studies later identified enteroviral sequences in the spinal cord or brainstem of 60 to 88 percent of patients with ALS, compared with 3 to 14 percent of controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]. Importantly, these enteroviral sequences were found to localize to neurons [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a multicenter French study, enterovirus RNA was found in 14.5 percent of 242 patients with ALS, compared with 7.6 percent of 354 controls, a statistically significant difference [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies such as these have led to the hypothesis of nonlytic, noncytopathic persistent viral infection, particularly of enteroviruses, as a cause of ALS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/62\">",
"     62",
"    </a>",
"    ]. Presumably, these viruses could infect motor neurons in this manner, evade the host's immune surveillance, spread from one motor neuron to the next, and turn on apoptosis of motor neurons. Long-term treatment with antiviral drugs could in theory prevent viral propagation and thus prevent death in motor neurons not yet infected by the virus.",
"   </p>",
"   <p>",
"    There is a report of one patient with ALS who may have shown some response to pleconaril, an anti-enteroviral drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/63\">",
"     63",
"    </a>",
"    ]. However, other studies have not supported the viral hypothesis of ALS etiopathogenesis, and enterovirus sequences or enterovirus RNA have not been found in the spinal cord or motor cortex of patients with ALS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36553/abstract/62-66\">",
"     62-66",
"    </a>",
"    ]. Because of these contradictory studies, the role of enteroviruses in ALS pathogenesis remains uncertain. Antiviral therapy is not yet recommended for patients with ALS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/57/8082?source=see_link\">",
"       \"Patient information: Poliomyelitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21841430\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poliovirus is transmitted by oral-fecal contact. During epidemics, it also may be transmitted by pharyngeal spread. Ninety to 95 percent of poliovirus infections are asymptomatic. There is an incubation period of 7 to 14 days. An asymptomatic primary (minor) transient viremia occurs, with spread of virus to the systemic reticuloendothelial tissue. In 4 to 8 percent of individuals, a second major viremia occurs, causing symptoms of the \"minor illness\" (abortive polio), which resembles the usual viral infection, including headache, sore throat, fever, nausea, vomiting, malaise, and fatigue. In a fraction of those with major viremia and abortive polio, involvement of the central nervous system then occurs. In some of these patients, the poliovirus then causes selective destruction of motor neurons, characterized by severe back, neck, and muscle pain, and the development of motor weakness. This paralysis occurs in only about 0.1 percent of all poliovirus infections. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Weakness due to poliomyelitis may range from involvement of one muscle or group of muscles to quadriplegia and respiratory failure. Tone is reduced, nearly always in an asymmetric manner. Proximal muscles usually are affected more than distal ones, and legs are affected more commonly than arms. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of poliomyelitis is suspected based on the clinical presentation and cerebrospinal fluid findings (",
"      <a class=\"graphic graphic_table graphicRef73307 \" href=\"mobipreview.htm?20/50/21291\">",
"       table 1",
"      </a>",
"      ).The cerebrospinal fluid shows a pleocytosis initially characterized by polymorphonuclear leukocytes, followed by a shift to lymphocytes. The cerebrospinal fluid protein is usually elevated. The diagnosis can be confirmed by virus isolation. Poliovirus can be isolated from throat secretions in the first week of illness, and from feces for several weeks. It rarely can be isolated from cerebrospinal fluid. The diagnosis can also be confirmed by polymerase chain reaction amplification of poliovirus RNA from cerebrospinal fluid or serologically. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of acute flaccid paralysis is summarized in the Table (",
"      <a class=\"graphic graphic_table graphicRef71165 \" href=\"mobipreview.htm?35/20/36171\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of poliomyelitis is supportive. Respiratory failure may develop, requiring mechanical ventilation. Patients with bulbar involvement require close monitoring of cardiovascular status because of the association with blood pressure fluctuations, circulatory collapse, and autonomic dysfunction. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment, course, and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because there are no effective treatments to restore motor neuron function after paralytic polio, prevention has been a mainstay of clinical and research efforts. In areas of the world where polio is endemic, primary immunization is performed with Sabin oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/58/35749?source=see_link\">",
"       poliovirus vaccine",
"      </a>",
"      (OPV). But, because it causes polio in one out of 2.5 million cases, it has been replaced by the Salk IPV in countries without polio, including the United States and most of Europe. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Polio vaccination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Paralytic disease associated with vaccination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Polio eradication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonpolio enteroviruses usually produce infections that are clinically inapparent. Although aseptic meningitis is the most common central nervous system manifestation of enteroviruses (followed by encephalitis), acute flaccid paralysis may sometimes result. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Nonpolio enteroviruses causing acute flaccid paralysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both HIV-1 and HTLV-1 have been implicated in a syndrome resembling amyotrophic lateral sclerosis (ALS), but the clinical presentations are atypical for ALS. In contrast, studies of postmortem central nervous system tissue and of cerebrospinal fluid from patients with unequivocal clinical evidence of ALS have revealed enterovirus more frequently than in controls, but the contribution of such viruses to ALS pathogenesis remains uncertain. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Viruses and amyotrophic lateral sclerosis syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Modlin, JF. Poliovirus. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 6th ed, Mandell, GL, Bennett, JE, Dolin, R (Eds), Elsevier, Philadelphia 2005. p.2141.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/2\">",
"      Mitka M. Happy 50th birthday, Salk vaccine. JAMA 2005; 293:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/3\">",
"      World Health Organization. Poliomyelitis in 1981. Wkly Epidemiol Rec 1982; 57:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/4\">",
"      Robbins FC, Nightingale EO. Selective primary health care: strategies for control of disease in the developing world. IX. Poliomyelitis. Rev Infect Dis 1983; 5:957.",
"     </a>",
"    </li>",
"    <li>",
"     DeBiasi, RL, Solbrig, MV, Tyler, KL. Infections of the nervous system: viral infections. In: Neurology in Clinical Practice, 4th ed, Bradley, WG, Daroff, RB, Fenichel, GM, Jankovic, J, (Eds), Butterworth Heineman, Philadelphia 2004. p.1515.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/6\">",
"      Mueller S, Wimmer E, Cello J. Poliovirus and poliomyelitis: a tale of guts, brains, and an accidental event. Virus Res 2005; 111:175.",
"     </a>",
"    </li>",
"    <li>",
"     Jubelt, B, Lipton, HL. Enterovirus infections. In: Handbook of Clinical Neurology, vol 56: Viral Disease, Vinken, PJ, Bruyn, GW, Klawans, HL, McKendall, RR (Eds), Elsevier, Amsterdam 1989. p.307.",
"    </li>",
"    <li>",
"     Cohen, JL. Enteroviruses and retroviruses. In: Harrison's Principles of Internal Medicine, 16th ed, Kasper, DL, Brunwald, E, Fauci, AS, et al (Eds), McGraw-Hill, New York 2005. p.1143.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/9\">",
"      Howard RS. Poliomyelitis and the postpolio syndrome. BMJ 2005; 330:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/10\">",
"      Rotbart HA, Webster AD, Pleconaril Treatment Registry Group. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis 2001; 32:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/11\">",
"      Desmond RA, Accortt NA, Talley L, et al. Enteroviral meningitis: natural history and outcome of pleconaril therapy. Antimicrob Agents Chemother 2006; 50:2409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/12\">",
"      Stuifbergen AK. Secondary conditions and life satisfaction among polio survivors. Rehabil Nurs 2005; 30:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/13\">",
"      SALK JE. Considerations in the preparation and use of poliomyelitis virus vaccine. J Am Med Assoc 1955; 158:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/14\">",
"      Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 1985; 151:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/15\">",
"      Palacios G, Oberste MS. Enteroviruses as agents of emerging infectious diseases. J Neurovirol 2005; 11:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/16\">",
"      Drebot MA, Mulders MN, Campbell JJ, et al. Molecular detection of an importation of type 3 wild poliovirus into Canada from The Netherlands in 1993. Appl Environ Microbiol 1997; 63:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/17\">",
"      Centers for Disease Control and Prevention (CDC). Tracking progress toward global polio eradication, 2010-2011. MMWR Morb Mortal Wkly Rep 2012; 61:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/18\">",
"      Centers for Disease Control and Prevention (CDC). Laboratory surveillance for wild and vaccine-derived polioviruses, January 2004-June 2005. MMWR Morb Mortal Wkly Rep 2005; 54:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/19\">",
"      Aylward RB, Linkins J. Polio eradication: mobilizing and managing the human resources. Bull World Health Organ 2005; 83:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/20\">",
"      Centers for Disease Control and Prevention (CDC). Outbreaks following wild poliovirus importations --- Europe, Africa, and Asia, January 2009-September 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/21\">",
"      Kaura G, Biswas T. India reaches milestone of no cases of wild poliovirus for 12 months. BMJ 2012; 344:e1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/22\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward interruption of wild poliovirus transmission--worldwide, January 2011-March 2012. MMWR Morb Mortal Wkly Rep 2012; 61:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/23\">",
"      Centers for Disease Control and Prevention (CDC). Poliomyelitis outbreak--Republic of the Congo, September 2010-February 2011. MMWR Morb Mortal Wkly Rep 2011; 60:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/24\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward poliomyelitis eradication--Nigeria, January 2004-July 2005. MMWR Morb Mortal Wkly Rep 2005; 54:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/25\">",
"      World Health Organization. Global eradication of poliomyelitis by the year 2000. Bull WHO 1988; 63:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/26\">",
"      Roberts L. Infectious disease. Polio eradication effort adds new weapon to its armory. Science 2005; 307:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/27\">",
"      Webster P. A polio-free world? Lancet 2005; 366:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/28\">",
"      Voroshilova, MK, Chumakov, MP. Poliomyelitis-like properties of AB-IV-coxsackie A7 group of viruses. Prog Med Virol 1959; 2:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/29\">",
"      Gear JH. Nonpolio causes of polio-like paralytic syndromes. Rev Infect Dis 1984; 6 Suppl 2:S379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/30\">",
"      Grist NR, Bell EJ. Paralytic poliomyelitis and nonpolio enteroviruses: studies in Scotland. Rev Infect Dis 1984; 6 Suppl 2:S385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/31\">",
"      Melnick JL. Enterovirus type 71 infections: a varied clinical pattern sometimes mimicking paralytic poliomyelitis. Rev Infect Dis 1984; 6 Suppl 2:S387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/32\">",
"      Huang CC, Liu CC, Chang YC, et al. Neurologic complications in children with enterovirus 71 infection. N Engl J Med 1999; 341:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/33\">",
"      Ooi MH, Wong SC, Lewthwaite P, et al. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol 2010; 9:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/34\">",
"      Chumakov M, Voroshilova M, Shindarov L, et al. Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol 1979; 60:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/35\">",
"      Shindarov LM, Chumakov MP, Voroshilova MK, et al. Epidemiological, clinical, and pathomorphological characteristics of epidemic poliomyelitis-like disease caused by enterovirus 71. J Hyg Epidemiol Microbiol Immunol 1979; 23:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/36\">",
"      Nagy G, Tak&aacute;tsy S, Kuk&aacute;n E, et al. Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol 1982; 71:217.",
"     </a>",
"    </li>",
"    <li>",
"     Hung, T, Kono, R. Neurologic complications of acute haemorrhagic conjunctivitis (a polio-like syndrome in adults). In: Handbook of clinical neurology, vol 38: Neuological Manifestations of Systemic Diseases, Part I, Vinken, PJ, Bruyn, GW, Klawans, HL (Eds), North-Holland Publishing Co, Amsterdam 1979. p.595.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/38\">",
"      Katiyar BC, Misra S, Singh RB, et al. Adult polio-like syndrome following Enterovirus 70 conjunctivitis (natural history of the disease). Acta Neurol Scand 1983; 67:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/39\">",
"      Wadia NH, Katrak SM, Misra VP, et al. Polio-like motor paralysis associated with acute hemorrhagic conjunctivitis in an outbreak in 1981 in Bombay, India: clinical and serologic studies. J Infect Dis 1983; 147:660.",
"     </a>",
"    </li>",
"    <li>",
"     Vejjajiva, A. Acute hemorrhagic conjunctivitis with nervous system complications. In: Handbook of Clinical Neurology, vol 56: Viral Disease, Vinken, PJ, Bruyn, GW, Klawans, HL, McKendall, RR (Eds), Elsevier, Amsterdam 1989. p.349.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/41\">",
"      da Silva EE, Winkler MT, Pallansch MA. Role of enterovirus 71 in acute flaccid paralysis after the eradication of poliovirus in Brazil. Emerg Infect Dis 1996; 2:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/42\">",
"      Takimoto S, Waldman EA, Moreira RC, et al. Enterovirus 71 infection and acute neurological disease among children in Brazil (1988-1990). Trans R Soc Trop Med Hyg 1998; 92:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/43\">",
"      Chan LG, Parashar UD, Lye MS, et al. Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis 2000; 31:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/44\">",
"      Saraswathy TS, Khairullah NS, Sinniah M, et al. Laboratory acute flaccid paralysis surveillance in Malaysia: a decade of commitment to the WHO global polio eradication initiative. Southeast Asian J Trop Med Public Health 2004; 35:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/45\">",
"      Bahri O, Rezig D, Nejma-Oueslati BB, et al. Enteroviruses in Tunisia: virological surveillance over 12 years (1992-2003). J Med Microbiol 2005; 54:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/46\">",
"      Yoshimura K, Kurashige T. A case of poliomyelitis-like syndrome. Brain Dev 1998; 20:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/47\">",
"      Grimwood K, Huang QS, Sadleir LG, et al. Acute flaccid paralysis from echovirus type 33 infection. J Clin Microbiol 2003; 41:2230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/48\">",
"      de Azevedo JP, Nascimento LR, Cortinovis MC, et al. Characterization of species B adenoviruses isolated from fecal specimens taken from poliomyelitis-suspected cases. J Clin Virol 2004; 31:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/49\">",
"      Moulignier A, Moulonguet A, Pialoux G, Rozenbaum W. Reversible ALS-like disorder in HIV infection. Neurology 2001; 57:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/50\">",
"      Verma A, Berger JR. ALS syndrome in patients with HIV-1 infection. J Neurol Sci 2006; 240:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/51\">",
"      Verma RK, Ziegler DK, Kepes JJ. HIV-related neuromuscular syndrome simulating motor neuron disease. Neurology 1990; 40:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/52\">",
"      MacGowan DJ, Scelsa SN, Waldron M. An ALS-like syndrome with new HIV infection and complete response to antiretroviral therapy. Neurology 2001; 57:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/53\">",
"      Berger JR, Espinosa PS, Kissel J. Brachial amyotrophic diplegia in a patient with human immunodeficiency virus infection: widening the spectrum of motor neuron diseases occurring with the human immunodeficiency virus. Arch Neurol 2005; 62:817.",
"     </a>",
"    </li>",
"    <li>",
"     Roman, GC, Vernant, J-C, Osame, M. HTLV-1-associated motor neuron disease. In: Handbook of Clinical Neurology, Vol. 15(59): Diseases of the Motor System. Vinken, PJ, Bruyn, GW, Klawans, HL (Eds), Elsevier, Amsterdam 1991. p.447.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/55\">",
"      Matsuzaki T, Nakagawa M, Nagai M, et al. HTLV-I-associated myelopathy (HAM)/tropical spastic paraparesis (TSP) with amyotrophic lateral sclerosis-like manifestations. J Neurovirol 2000; 6:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/56\">",
"      Silva MT, Leite AC, Alamy AH, et al. ALS syndrome in HTLV-I infection. Neurology 2005; 65:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/57\">",
"      Woodall CJ, Riding MH, Graham DI, Clements GB. Sequences specific for enterovirus detected in spinal cord from patients with motor neurone disease. BMJ 1994; 308:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/58\">",
"      Berger MM, Kopp N, Vital C, et al. Detection and cellular localization of enterovirus RNA sequences in spinal cord of patients with ALS. Neurology 2000; 54:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/59\">",
"      Giraud P, Beaulieux F, Ono S, et al. Detection of enteroviral sequences from frozen spinal cord samples of Japanese ALS patients. Neurology 2001; 56:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/60\">",
"      Woodall CJ, Graham DI. Evidence for neuronal localisation of enteroviral sequences in motor neurone disease/amyotrophic lateral sclerosis by in situ hybridization. Eur J Histochem 2004; 48:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/61\">",
"      Vandenberghe N, Leveque N, Corcia P, et al. Cerebrospinal fluid detection of enterovirus genome in ALS: a study of 242 patients and 354 controls. Amyotroph Lateral Scler 2010; 11:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/62\">",
"      Ravits J. Sporadic amyotrophic lateral sclerosis: a hypothesis of persistent (non-lytic) enteroviral infection. Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/63\">",
"      Ansevin CF. Treatment of ALS with pleconaril. Neurology 2001; 56:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/64\">",
"      Swanson NR, Fox SA, Mastaglia FL. Search for persistent infection with poliovirus or other enteroviruses in amyotrophic lateral sclerosis-motor neurone disease. Neuromuscul Disord 1995; 5:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/65\">",
"      Walker MP, Schlaberg R, Hays AP, et al. Absence of echovirus sequences in brain and spinal cord of amyotrophic lateral sclerosis patients. Ann Neurol 2001; 49:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36553/abstract/66\">",
"      Nix WA, Berger MM, Oberste MS, et al. Failure to detect enterovirus in the spinal cord of ALS patients using a sensitive RT-PCR method. Neurology 2004; 62:1372.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5143 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-64F316EBC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_44_36553=[""].join("\n");
var outline_f35_44_36553=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21841430\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ENTEROVIRUS CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      POLIOVIRUS AND POLIOMYELITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment, course, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Polio vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Paralytic disease associated with vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Polio eradication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NONPOLIO ENTEROVIRUSES CAUSING ACUTE FLACCID PARALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Epidemiology subsequent to polio eradication efforts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      VIRUSES AND AMYOTROPHIC LATERAL SCLEROSIS SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      HIV-1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      HTLV-1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31632106\">",
"      Enteroviruses and ALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21841430\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5143\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5143|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/50/21291\" title=\"table 1\">",
"      Evaluation AFP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/20/36171\" title=\"table 2\">",
"      Causes acute flaccid paralysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/33/3611\" title=\"table 3\">",
"      Polio eradication",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22808?source=related_link\">",
"      Acute and early HIV infection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/36/37448?source=related_link\">",
"      Botulism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/9/35992?source=related_link\">",
"      Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40280?source=related_link\">",
"      Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/47/22264?source=related_link\">",
"      Clinical manifestations and diagnosis of West Nile virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10439?source=related_link\">",
"      Clinical manifestations and diagnosis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15735?source=related_link\">",
"      Clinical manifestations and diagnosis of inclusion body myositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22423?source=related_link\">",
"      Clinical manifestations of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16938?source=related_link\">",
"      Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23450?source=related_link\">",
"      Epidemiology and pathogenesis of amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/26/41383?source=related_link\">",
"      Epidemiology, pathogenesis, treatment, and prevention of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/38/29287?source=related_link\">",
"      Epidemiology, pathophysiology and clinical manifestations of diphtheria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40808?source=related_link\">",
"      Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27705?source=related_link\">",
"      Overview of Guillain-Barr&eacute; syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/45/41688?source=related_link\">",
"      Overview of neuromuscular junction toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=related_link\">",
"      Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/57/8082?source=related_link\">",
"      Patient information: Poliomyelitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/52/17223?source=related_link\">",
"      Poliovirus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/45/5849?source=related_link\">",
"      Post-polio syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_44_36554="Approach to abdominal pain and the acute abdomen in pregnant and postpartum women";
var content_f35_44_36554=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to abdominal pain and the acute abdomen in pregnant and postpartum women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/44/36554/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/44/36554/contributors\">",
"     Charlie C Kilpatrick, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/44/36554/contributors\">",
"     Francisco J Orejuela, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/44/36554/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/44/36554/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/44/36554/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/44/36554/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/44/36554/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/44/36554/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to abdominal pain and the acute abdomen in pregnancy is similar to that in the nonpregnant state, with some additional challenges. For example, the clinician needs to consider",
"    <span class=\"nowrap\">",
"     physiologic/anatomic",
"    </span>",
"    alterations related to pregnancy, gestational age and fetal well-being, and causes of acute abdomen that may be more common due to the pregnant state or related to obstetrical complications. Indicated diagnostic imaging and interventions should be performed since delay in diagnosis and treatment can increase maternal and",
"    <span class=\"nowrap\">",
"     fetal/newborn",
"    </span>",
"    morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review issues specific to the diagnostic evaluation and management of abdominal pain and acute abdomen in pregnant and postpartum women. The approach to abdominal pain and acute abdomen in other populations is discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/24/40323?source=see_link\">",
"       \"History and physical examination in adults with abdominal pain\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=see_link\">",
"       \"Diagnostic approach to abdominal pain in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=see_link\">",
"       \"Differential diagnosis of abdominal pain in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/44/17095?source=see_link\">",
"       \"Evaluation of acute pelvic pain in women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal in the evaluation of patients with abdominal pain is to identify those who have a serious or even life-threatening etiology for their symptoms and require urgent intervention. In pregnant women, the etiology may be related to pregnancy and may directly or indirectly affect the fetus, as well.",
"   </p>",
"   <p>",
"    Pregnancy complicates the diagnosis of abdominal pain because",
"    <span class=\"nowrap\">",
"     physiologic/anatomic",
"    </span>",
"    changes associated with pregnancy can mimic clinical features of",
"    <span class=\"nowrap\">",
"     medical/surgical",
"    </span>",
"    disorders associated with abdominal pain, thus creating diagnostic uncertainty. Concerns about fetal safety may also complicate diagnostic evaluation.",
"   </p>",
"   <p>",
"    When evaluating the pregnant women with abdominal pain, the following principles should be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild to moderate abdominal discomfort is a common, usually transient, complaint in normal pregnancy. It can be due to a number of normal physiological entities, such as the enlarging uterus, fetal position or movement, Braxton-Hicks uterine contractions (ie, contractions not associated with",
"      <span class=\"nowrap\">",
"       labor/cervical",
"      </span>",
"      changes), and possibly the round ligaments. Pain related to the round ligaments and enlarging uterus is more common in early pregnancy, while pain related to contractions and the fetus is more common later in pregnancy, especially in the third trimester. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44808?source=see_link\">",
"       \"Clinical manifestations and diagnosis of early pregnancy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In contrast, pain that is severe, sudden, constant, associated with other symptoms (eg, nausea, vomiting, vaginal bleeding), or in the upper abdomen suggests a disease process. The presence of peritoneal signs (rebound tenderness, abdominal guarding) is never normal in pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/2\">",
"       2",
"      </a>",
"      ]. These patients require prompt maternal-fetal evaluation.",
"     </li>",
"     <li>",
"      Nausea and vomiting is a common feature of early pregnancy, and usually abates by 20 weeks of gestation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41207?source=see_link\">",
"       \"Clinical features and evaluation of nausea and vomiting of pregnancy\"",
"      </a>",
"      .) Nausea and vomiting is not a normal manifestation of pregnancy when it occurs with abdominal pain, fever, diarrhea, headache, or localized abdominal findings. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16120?source=see_link\">",
"       \"Approach to the adult with nausea and vomiting\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The uterus becomes an abdominal organ, enlarging beyond the pelvis by 12 weeks of gestation. This enlargement may make it difficult to localize pain as it can impede physical examination, affect the normal location of pelvic and abdominal organs, and mask or delay peritoneal signs (rebound, guarding) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/2\">",
"       2",
"      </a>",
"      ]. The laxity of the abdominal wall may also diminish peritoneal signs (guarding, rebound).",
"     </li>",
"     <li>",
"      The enlarged uterus may compress the urinary tract, leading to hydroureter and hydronephrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/3\">",
"       3",
"      </a>",
"      ] or cause aortocaval compression, resulting in dizziness or syncope when the pregnant woman is in a supine position [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/4\">",
"       4",
"      </a>",
"      ]. These physiological changes mimic some of the signs of nephrolithiasis and cardiac arrhythmia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24072?source=see_link\">",
"       \"Renal and urinary tract physiology in normal pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33479?source=see_link\">",
"       \"Acute kidney injury (acute renal failure) in pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20105?source=see_link\">",
"       \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The high progesterone concentration during pregnancy decreases lower esophageal sphincter tone, small bowel and colonic motility, gallbladder emptying, and ureteral tone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/5\">",
"       5",
"      </a>",
"      ]. These physiologic changes are important in the pathogenesis and diagnosis of conditions such as gastroesophageal reflux, constipation, cholelithiasis, and nephrolithiasis, all of which may be associated with abdominal pain. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9160?source=see_link\">",
"       \"Maternal gastrointestinal tract adaptation to pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Physiologic changes in hematologic parameters may mimic infection and occult hemorrhage, making diagnosis of these disorders more difficult:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      White blood cell counts increase to a normal range of 10,000 to 14,000",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      during pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/6\">",
"       6",
"      </a>",
"      ], and in labor the white blood cell count may be as high as 20,000 to 30,000",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      returning to normal prepregnancy levels at about one week postpartum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/7\">",
"       7",
"      </a>",
"      ]. However, bandemia is not a normal variant of pregnancy and its presence suggests infection until proven otherwise.",
"     </li>",
"     <li>",
"      A larger increase in plasma volume than in red cell volume results in physiologic anemia. The modest decrease in hemoglobin concentration (normal hemoglobin &ge;10.5 to 11.0",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      coupled with the normal modest increase in heart rate (by 10 to 15 beats per minute) can be mistaken for signs of mild hemorrhage. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21703?source=see_link\">",
"       \"Hematologic changes in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The range of normal for other laboratory values may also be altered in pregnancy (",
"      <a class=\"graphic graphic_table graphicRef81137 \" href=\"mobipreview.htm?37/33/38424\">",
"       table 1",
"      </a>",
"      ) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/7/14454?source=see_link\">",
"       \"Normal reference ranges for laboratory values in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15372999\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15373475\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnostic approach to abdominal pain in adults\", section on 'History'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnostic approach to abdominal pain in adults\", section on 'Physical examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/24/40323?source=see_link\">",
"     \"History and physical examination in adults with abdominal pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the usual diagnostic evaluation of adults with abdominal pain, the fetal heart rate should be documented. Continuous fetal heart rate monitoring is usually appropriate in pregnancies that have reached 23 to 24 weeks of gestation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/26/30121?source=see_link\">",
"     \"Overview of fetal assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2232?source=see_link\">",
"     \"Antepartum fetal heart rate assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to their medical and surgical history, pregnant women should be asked about their past and current obstetrical history, and whether they have had any vaginal bleeding or leaking fluid (rupture of the fetal membranes). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/6/15465?source=see_link\">",
"     \"Overview of the etiology and evaluation of vaginal bleeding in pregnant women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15866?source=see_link\">",
"     \"Preterm premature rupture of membranes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The uterine examination should evaluate size, tone, tenderness, and, in the second half of pregnancy, frequency of contractions. The uterus is normally nontender and soft, like any other relaxed muscle. Rupture of membranes and cervical",
"    <span class=\"nowrap\">",
"     dilation/effacement",
"    </span>",
"    should be assessed. Obstetric and non-obstetric disorders may cause uterine contractions, which may result in cervical change (labor). Uterine tenderness or rigidity is abnormal, and may be due to labor, abruptio placenta, uterine rupture, or intrauterine infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15373027\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a thorough history and physical examination, laboratory tests should be obtained to narrow the differential diagnosis. In general, we suggest:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count with differential",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"     <li>",
"      Liver and pancreatic function tests (aminotransferases, bilirubin, amylase, lipase)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the presence of fever or unstable vital signs, blood and urine cultures should be performed. Women with hemodynamic instability should have blood sent for coagulation studies and type and crossmatch. Electrolytes and renal function tests can be useful in women who are vomiting or anorectic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnostic approach to abdominal pain in adults\", section on 'History'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnostic approach to abdominal pain in adults\", section on 'Physical examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=see_link&amp;anchor=H21#H21\">",
"     \"Diagnostic approach to abdominal pain in adults\", section on 'Diagnostic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15373132\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound is typically the first-line modality for diagnostic imaging of the abdomen in pregnant women since it is widely available, portable, nonionizing, and its diagnostic performance is often adequate. When ultrasound findings are equivocal or uncertain, then the choice of the second-line modality depends on the differential diagnosis and should take into account availability, diagnostic performance, and fetal radiation exposure. When indicated, use of magnetic resonance (MR) imaging is preferable to computed tomography (CT) because it avoids ionizing radiation and, for diagnosis of many disorders, performs as well as, or better than, CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2678326\">",
"    <span class=\"h3\">",
"     Ionizing radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns about the possible fetal effects of ionizing radiation should not prevent medically indicated diagnostic procedures during pregnancy using the best available modality for the clinical situation. A delay in diagnosis can increase the risk of an adverse maternal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetal outcome. When procedures requiring ionizing radiation are necessary, various techniques can be employed to minimize the radiation dose to adhere to the ALARA principle: As Low As Reasonably Achieved. Almost all diagnostic radiological procedures are associated with exposures that are below the threshold for congenital malformations, growth restriction, or developmental delay. Whether there is a small increase in risk of carcinogenesis is controversial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chest and abdominal radiographs are commonly used in evaluation of adults with abdominal pain. The estimated fetal absorption per chest X-ray is &lt;0.01 mGy (&lt;0.001 rad); this dose is well below doses that have been associated with any short- or long-term adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/11\">",
"     11",
"    </a>",
"    ]. The estimated fetal absorption for abdominal X-rays is 1 to 4.2 mGy (0.1 to 0.42 rad), which is also below doses that have been associated with short- or long-term adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15373161\">",
"    <span class=\"h2\">",
"     Laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopy is sometimes indicated in the evaluation of acute pelvic or abdominal pain, especially when the diagnosis is not clear after less invasive evaluations and the differential diagnoses include potentially life-threatening or organ-threatening disorders. It is usually performed in the first, second, and early third trimester. Based on retrospective evaluation and survey data, laparoscopic surgery for evaluation of pelvic or abdominal pain in pregnancy appears to be as safe as laparotomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8727?source=see_link\">",
"     \"Laparoscopic surgery in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When surgery is planned, the appropriate services (Obstetrics, General Surgery, Anesthesia, Pediatrics) should be consulted. Management of pregnant women undergoing surgery may require modifications to the general approach used in nonpregnant women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15482?source=see_link\">",
"     \"Management of pregnant women undergoing nonobstetric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS OF ABDOMINAL PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of abdominal pain or the acute abdomen in pregnant women is similar to that in the nonpregnant state, with a few conditions specific to pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pregnancy-related causes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2677824\">",
"    <span class=\"h3\">",
"     First half of pregnancy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1853906811\">",
"    <span class=\"h4\">",
"     Miscarriage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Miscarriage is defined as the loss of a pregnancy before 20 weeks of gestation. Signs and symptoms include mild to moderate midline crampy pelvic pain and mild to moderate vaginal bleeding. Speculum and pelvic examinations are the first step in the diagnostic evaluation. If no products of conception are identified grossly, then ultrasonography and serial quantitative serum human chorionic gonadotropin hormone (hCG) levels are the most useful follow-up tests of women suspected of carrying a nonviable pregnancy. The sonographic signs of a nonviable pregnancy vary with gestational age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/23/19834?source=see_link\">",
"     \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Extrauterine (ectopic) pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extrauterine (ectopic) pregnancies usually occur in the fallopian tube, but can occur elsewhere (eg, attached to abdominal viscera or within the cervix or a cesarean delivery scar). Rarely, an extrauterine pregnancy occurs concurrently with an intrauterine pregnancy; these heterotopic pregnancies can be difficult to diagnose. A pregnancy conceived via assisted reproductive technology (eg, in vitro fertilization [IVF]) is a strong risk factor.",
"   </p>",
"   <p>",
"    Clinical manifestations are usually related to free blood in the peritoneal cavity due to extrauterine pregnancy rupture or bleeding, and vary depending upon the location. Abdominal pain is a common symptom of all types of extrauterine pregnancy; vaginal bleeding, nausea, and vomiting may also occur. Blood in the peritoneal cavity can be identified by ultrasound examination or culdocentesis.",
"   </p>",
"   <p>",
"    Given the rise in the number of first trimester ultrasounds performed in the United States, the diagnosis of extrauterine pregnancy is usually based upon results from ultrasound examination in the early first trimester and hCG testing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/4/16457?source=see_link\">",
"     \"Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2677879\">",
"    <span class=\"h3\">",
"     Second half of pregnancy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2677706\">",
"    <span class=\"h4\">",
"     Labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Labor (term or preterm) should be considered in the differential diagnosis of abdominal pain in pregnant women. It is a clinical diagnosis defined by uterine contractions of increasing frequency, intensity, and duration that cause cervical dilation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    effacement. The presence of light vaginal bleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rupture of membranes increase diagnostic certainty in women with mild cervical dilation or effacement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/30/5608?source=see_link\">",
"     \"Overview of preterm labor and birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2677794\">",
"    <span class=\"h4\">",
"     Placental abruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute abruption (ie, decidual hemorrhage leading to the premature separation of the placenta prior to delivery) classically presents with vaginal bleeding, abdominal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    back pain, uterine tenderness, uterine rigidity, and uterine contractions; the fetal heart rate pattern may be nonreassuring. If significant placental separation occurs, maternal disseminated intravascular coagulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetal death commonly occur. A retroplacental or subchorionic clot is the classic ultrasound finding of placental abruption, but is not always present. Diagnosis is based on clinical findings and delivery is usually indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29417?source=see_link\">",
"     \"Placental abruption: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34663?source=see_link\">",
"     \"Placental abruption: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2677735\">",
"    <span class=\"h4\">",
"     Uterine rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine rupture is a rare and often catastrophic event. Signs and symptoms include nonreassuring fetal heart rate tracing or fetal death, uterine tenderness, peritoneal irritation, vaginal bleeding, loss of fetal station, and shock.",
"   </p>",
"   <p>",
"    Most uterine ruptures occur in laboring women with a prior cesarean delivery or prior transmyometrial uterine surgery (eg, myomectomy). Rupture of the unscarred uterus during labor is rare; risk factors include grand multiparity, dystocia (malpresentation, macrosomia), obstetrical procedures (breech extraction, uterine instrumentation, cephalic version), and use of uterotonic drugs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5290?source=see_link&amp;anchor=H15065397#H15065397\">",
"     \"Choosing the route of delivery after cesarean birth\", section on 'Uterine rupture'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/4/44102?source=see_link\">",
"     \"Rupture of the unscarred uterus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Uterine rupture may also occur before labor. Spontaneous rupture may occur in women with a scarred uterus, but usually results from sharp or blunt abdominal trauma or rupture of an interstitial or cornual pregnancy or pregnancy in a rudimentary uterine horn. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/2/22569?source=see_link&amp;anchor=H18#H18\">",
"     \"Trauma in pregnancy\", section on 'Uterine rupture'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21566339\">",
"    <span class=\"h4\">",
"     Pregnancy-related liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy-related liver diseases can cause epigastric or right upper quadrant abdominal pain. These disorders (severe preeclampsia, HELLP syndrome, and acute fatty liver of pregnancy) have over-lapping features and can be difficult to distinguish (",
"    <a class=\"graphic graphic_figure graphicRef57913 \" href=\"mobipreview.htm?12/14/12514\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76975 \" href=\"mobipreview.htm?42/60/43979\">",
"     table 2B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h5\">",
"     Severe preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preeclampsia refers to a syndrome characterized by the new onset of hypertension and proteinuria after 20 weeks of gestation in a previously normotensive woman; liver involvement is a sign of severe disease (",
"    <a class=\"graphic graphic_table graphicRef79977 graphicRef76975 \" href=\"mobipreview.htm?34/20/35148\">",
"     table 2A-B",
"    </a>",
"    ). The clinical manifestations of liver involvement include right upper quadrant or epigastric pain, elevated transaminases and, in the most severe cases, subcapsular hemorrhage or hepatic rupture. The diagnosis is clinical, based on findings on physical examination (hypertension) and laboratory results (proteinuria with or without thrombocytopenia, elevated liver function tests, elevated creatinine level), as well as the presence of symptoms (persistent headache, scotomata, epigastric pain). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=see_link\">",
"     \"Preeclampsia: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21566370\">",
"    <span class=\"h5\">",
"     HELLP syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;HELLP syndrome refers to a syndrome characterized by Hemolysis with a microangiopathic blood smear, Elevated Liver enzymes, and a Low Platelet count. The most common clinical presentation is abdominal pain and tenderness in the midepigastrium, right upper quadrant, or below the sternum. Many women also have nausea, vomiting, and malaise, which may be mistaken for a nonspecific viral illness or viral hepatitis, particularly if the serum aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) are markedly elevated. Hypertension (blood pressure",
"    <span class=\"nowrap\">",
"     &ge;140/90",
"    </span>",
"    mm Hg) and proteinuria are present in approximately 85 percent of cases, but it is important to remember that either or both may be absent in women with otherwise severe HELLP syndrome. Hepatic rupture is rare and is a surgical emergency; if rupture is suspected, ultrasound examination may show intra- or extra-hepatic bleeding, but hepatic complications are best characterized by magnetic resonance (MR) imaging or computed tomography (CT). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17897?source=see_link\">",
"     \"HELLP syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h5\">",
"     Acute fatty liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute fatty liver occurs in the second half of pregnancy, usually in the third trimester. The most frequent initial symptoms are nausea or vomiting (approximately 75 percent of patients), abdominal pain (particularly epigastric, 50 percent), anorexia, and jaundice. As discussed above, nausea and vomiting during the second half of pregnancy should be considered abnormal and requires further evaluation. About one-half of patients have signs of preeclampsia at presentation or at some time during the course of illness.",
"   </p>",
"   <p>",
"    The diagnosis of acute fatty liver of pregnancy is usually made clinically based upon the setting, presentation, and compatible laboratory and imaging results. Laboratory tests that are helpful include aminotransferases, bilirubin, coagulation studies, electrolytes, glucose, uric acid, creatinine, and a white blood cell count. Imaging tests of the liver are primarily used to exclude other diagnoses, such as a hepatic infarct or hematoma, although some authors have reported finding fat on ultrasound, CT, or MR. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24166?source=see_link\">",
"     \"Acute fatty liver of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21566319\">",
"    <span class=\"h4\">",
"     Intraamniotic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs and symptoms of intraamniotic infection include fever, abdominal pain, uterine tenderness, leukocytosis, maternal and fetal tachycardia, and uterine contractions. It is most common in the setting of premature rupture of the fetal membranes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42761?source=see_link\">",
"     \"Intraamniotic infection (chorioamnionitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2682620\">",
"    <span class=\"h4\">",
"     Spontaneous hemoperitoneum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous hemoperitoneum in pregnancy is a rare life-threatening disorder; 25 cases have been reported in the past 2 decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/12\">",
"     12",
"    </a>",
"    ]. The patients presented with sudden onset of abdominal pain in the second half of pregnancy with hypovolemic shock",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abnormal fetal heart rate. Exploratory laparotomy revealed 500 to 4000 mLs of blood in the abdomen, usually from bleeding superficial",
"    <span class=\"nowrap\">",
"     veins/varicosities",
"    </span>",
"    on the posterior surface of the uterus or the parametrium. Risk factors included nulliparity and history of endometriosis. Biopsy of the bleeding site was done in five cases and all identified endometriosis. Timely intervention and control of bleeding allowed about half of the pregnancies to continue normally; the remainder ended in stillbirth or neonatal death. There were no maternal deaths.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4870065\">",
"    <span class=\"h4\">",
"     Uterine incarceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typically, patient&rsquo;s with uterine incarceration present at 14 to 16 weeks of gestation with symptoms related to pressure on the anatomic structures adjacent to the entrapped enlarging uterus. The most common symptoms are pain and progressive difficulty voiding. The pain may be abdominal, suprapubic, or in the back, or may be limited to pelvic discomfort or a feeling of pelvic fullness. Urinary symptoms include frequency, dysuria, sensation of incomplete emptying, voiding small volumes due to overflow incontinence, and, often, urinary retention.&nbsp;The diagnosis is based on characteristic findings on physical and ultrasound examination after the first trimester: severe anterior displacement of the cervix and the uterus filling the posterior pelvis below the sacral promontory. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21334?source=see_link\">",
"     \"Incarcerated gravid uterus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2682683\">",
"    <span class=\"h4\">",
"     Arterial dissection and rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dissection and rupture of arterial aneurysms (splenic, renal, uterine, ovarian, aorta) have also been described, mostly in case reports, and appear to be related to the physiologic and hemodynamic changes of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/13-19\">",
"     13-19",
"    </a>",
"    ]. Women with Marfan syndrome, Ehlers Danlos syndrome, or Turner syndrome are particularly at risk. Patients present with sudden onset abdominal pain, free peritoneal fluid, sudden hemodynamic collapse and, often, failure to correctly identify the cause prior to exploratory laparotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/13\">",
"     13",
"    </a>",
"    ]. Splenic artery aneurysm occurs in women without connective tissue disease and has a strong association with pregnancy. (See",
"    <a class=\"local\" href=\"#H15372650\">",
"     'Disorders of the spleen'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nonpregnancy-related causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;An extensive list of causes of abdominal pain is provided in the tables (",
"    <a class=\"graphic graphic_table graphicRef70233 graphicRef60310 \" href=\"mobipreview.htm?25/47/26366\">",
"     table 3A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef61375 \" href=\"mobipreview.htm?23/54/24419\">",
"     figure 2",
"    </a>",
"    ). The location of the pain can be helpful in differential diagnosis, but is not pathognomonic, especially during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15371695\">",
"    <span class=\"h3\">",
"     Pain in the upper abdomen",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2683327\">",
"    <span class=\"h4\">",
"     Gastroesophageal reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroesophageal reflux disease (GERD) is more common during pregnancy. The most common symptoms are heartburn (pyrosis), regurgitation, and dysphagia; other symptoms include chest pain, water brash, globus sensation, odynophagia, and nausea. A presumptive diagnosis can be based on clinical symptoms. Indications for additional evaluation are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15371778\">",
"    <span class=\"h4\">",
"     Gallbladder disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy predisposes to formation of gallstone (cholelithiasis). The presentation of gallstone disease during pregnancy is not significantly different than in the nonpregnant state. Affected patients typically complain of deep and gnawing pain that is occasionally sharp, colicky, and severe. The pain is localized in the right upper quadrant or epigastrium. There is often a history of fatty food ingestion one hour or more before onset of pain. As the gallbladder relaxes, the stones often fall back from the cystic duct. As a result, the attack reaches a crescendo over a number of hours and then resolves completely. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28201?source=see_link\">",
"     \"Gallstone disease in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute cholecystitis refers to a syndrome of right upper quadrant pain that is steady and severe, fever, tachycardia, and leukocytosis associated with gallbladder inflammation, which is usually related to gallstone disease. Murphy&rsquo;s sign is variably positive. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ultrasonography is the most reliable method for making the diagnosis of gallstones and acute or chronic cholecystitis. The white blood cell count and alkaline phosphatase level are normally elevated in pregnancy, which reduces the diagnostic usefulness of these tests. However, significant elevations of the transaminases and alkaline phosphatase or direct bilirubin should raise the possibility of a common bile duct stone, cholangitis, or the Mirizzi syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28201?source=see_link&amp;anchor=H215890#H215890\">",
"     \"Gallstone disease in pregnant women\", section on 'Diagnostic testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44565?source=see_link\">",
"     \"Mirizzi syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15371809\">",
"    <span class=\"h4\">",
"     Acute hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy generally does not affect the course of hepatitis A, B, or C, whereas women with hepatitis E in the third trimester are predisposed to severe clinical disease. Cytomegalovirus, Epstein-Barr virus, and adenoviruses can also cause hepatitis in association with systemic infection. Constitutional symptoms of hepatitis include anorexia, nausea, jaundice, and right upper quadrant discomfort. The diagnosis is based on characteristic laboratory findings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/24/14726?source=see_link\">",
"     \"Intercurrent hepatobiliary disease during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26198?source=see_link\">",
"     \"Approach to liver disease occurring during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15371889\">",
"    <span class=\"h4\">",
"     Pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pancreatitis is a rare complication of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]; most cases are related to gallstone disease. Almost all patients have acute and persistent upper abdominal pain, which may radiate to the back, may be relieved with leaning forward, and may be accompanied by fever and postprandial nausea and vomiting.",
"   </p>",
"   <p>",
"    The range of normal serum amylase and lipase levels are similar in healthy pregnant and nonpregnant women; significantly elevated values should be considered pathologic (",
"    <a class=\"graphic graphic_table graphicRef81137 \" href=\"mobipreview.htm?37/33/38424\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. Ultrasound can be used to look for choledocholithiasis and pseudocyst formation. If further imaging is needed, MR may be helpful. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/41/13976?source=see_link\">",
"     \"ERCP in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15371940\">",
"    <span class=\"h4\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonia involving the lower lobes of the lung is a common cause of abdominal pain syndromes, presumably related to diaphragmatic irritation, and may be confused with acute cholecystitis or, rarely, an acute abdomen. Abdominal pain is occasionally the sole presenting complaint in a patient with lower lobe pneumonia. The estimated fetal absorption per chest X-ray is &lt;0.01 mGy (&lt;0.001 rad); this dose is well below doses that have been associated with any short- or long-term adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36344?source=see_link\">",
"     \"Treatment of respiratory infections in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15372127\">",
"    <span class=\"h4\">",
"     Bowel obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of bowel obstruction during pregnancy increases as the uterus enlarges into the upper abdomen with advancing gestation. Adhesions and volvulus are the most common causes of the obstruction; intussusception is less common and hernias are rare, but should be suspected in those patients with a history of gastric bypass surgery who present with abdominal pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/26\">",
"     26",
"    </a>",
"    ]. Volvulus is more common during pregnancy than in the nonpregnant state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical manifestations of bowel obstruction include crampy abdominal pain with vomiting and obstipation. As discussed above, although nausea and vomiting is common and often a normal symptom of the first half of pregnancy, new onset later in pregnancy or coexistent abdominal pain or peritoneal signs are not normal and require evaluation. Other potential findings inconsistent with nausea and vomiting of pregnancy include abdominal distention, fever, and leukocytosis.",
"   </p>",
"   <p>",
"    Diagnosis and treatment are similar to that in nonpregnant individuals. Ultrasound may show dilated loops of bowel with air-fluid levels; flat and upright radiographs are more useful for looking for typical findings of obstruction and progressive bowel dilation over time (see",
"    <a class=\"local\" href=\"#H2678326\">",
"     'Ionizing radiation'",
"    </a>",
"    above). MR helps to characterize the site and degree of obstruction. Aggressive intervention is warranted because delay in treatment increases maternal and fetal morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8807?source=see_link\">",
"     \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14058?source=see_link\">",
"     \"Small bowel obstruction: Causes and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8663?source=see_link\">",
"     \"Cecal volvulus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26453?source=see_link\">",
"     \"Sigmoid volvulus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27945?source=see_link&amp;anchor=H48712524#H48712524\">",
"     \"Fertility and pregnancy after bariatric surgery\", section on 'Bowel obstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15372490\">",
"    <span class=\"h4\">",
"     Perforated ulcer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peptic ulcer disease is uncommon in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/28\">",
"     28",
"    </a>",
"    ]. Symptoms include nausea, vomiting, and epigastric pain, which is often worse at night and postprandially. In contrast, gastrointestinal reflux disease is common in pregnancy and characterized by both regurgitation and pain, which is worse postprandially and with recumbency.",
"   </p>",
"   <p>",
"    Ulcer perforation should be suspected in patients with a history of peptic ulcer symptoms who develop the sudden onset of severe, diffuse abdominal pain. The characteristics of the pain and associated symptoms and physical findings (eg, tachycardia, low temperature, peritoneal signs) evolve over the first 12 hours after perforation.",
"   </p>",
"   <p>",
"    Rapid diagnosis is essential, since the prognosis is excellent within the first 6 hours, but deteriorates with more than a 12-hour delay. Perforation is largely a clinical diagnosis with the history and physical examination providing essential clues. If imaging is required, plain abdominal x-rays are typically obtained first to detect diagnostic free air (see",
"    <a class=\"local\" href=\"#H2678326\">",
"     'Ionizing radiation'",
"    </a>",
"    above), although about 10 to 20 percent of patients with a perforated duodenal ulcer will not have free air. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40282?source=see_link&amp;anchor=H4460621#H4460621\">",
"     \"Overview of the complications of peptic ulcer disease\", section on 'Perforation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15372650\">",
"    <span class=\"h4\">",
"     Disorders of the spleen",
"    </span>",
"    &nbsp;&mdash;&nbsp;In asymptomatic women, a curvilinear or signet-ring shaped calcification on an abdominal x-ray is strongly suggestive of splenic artery aneurysm (see",
"    <a class=\"local\" href=\"#H2678326\">",
"     'Ionizing radiation'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rupture often occurs during pregnancy, usually in the third trimester, and is typically a catastrophic event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. However, 20 to 25 percent of patients have an initial small, contained rupture that occurs hours before hemorrhage with circulatory collapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/32\">",
"     32",
"    </a>",
"    ]. Presenting symptoms include diffuse abdominal pain centered in the midline or left upper quadrant and radiating to the shoulder, anorexia, nausea, vomiting, syncope, and diarrhea or constipation. If the patient is in hemorrhagic shock, immediate laparotomy should be performed with ligation of the splenic artery and splenectomy if the source is a splenic artery aneurysm.",
"   </p>",
"   <p>",
"    The wandering spleen syndrome is a rare cause of acute abdominal pain that is usually seen in younger adolescents and children, although it can occur in adults. Patients typically present with acute left upper quadrant pain associated with an abdominal mass. Ultrasound can help make the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15373413\">",
"    <span class=\"h4\">",
"     Hiatal hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common symptoms of hiatal hernia are epigastric or substernal pain, postprandial fullness, substernal fullness, nausea, and retching. The pain can be severe if the hernia incarcerates. Bariatric surgery increases the risk of hiatal hernia. The diagnosis is often made on the basis of characteristic clinical symptoms and findings on chest x-ray (see",
"    <a class=\"local\" href=\"#H2678326\">",
"     'Ionizing radiation'",
"    </a>",
"    above). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/22/7527?source=see_link\">",
"     \"Hiatus hernia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1057508\">",
"    <span class=\"h4\">",
"     Rectus sheath hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rectus sheath hematoma is a rare cause of acute upper abdominal pain in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/35\">",
"     35",
"    </a>",
"    ]. Risk factors include female gender, coagulation disorders, anticoagulant use, trauma, abdominal straining (coughing, exercising, vomiting), degenerative muscular disease, prior abdominal surgery, obesity, and pregnancy. Classic findings include abdominal pain and an abdominal mass that remains unchanged with contraction of the rectus muscles. Periumbilical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    flank ecchymosis may be present, and hypotension can occur with severe bleeding. Although ultrasound is typically the first-line imaging study (sensitivity 85 to 96 percent), CT is 100 percent sensitive in the diagnosis when the hematoma is less than 5 days duration. In addition to anemia, laboratory evaluation may show elevated transaminases as a result of trauma to skeletal muscle. If the hematoma is not expanding, most patients will respond to conservative measures (eg, fluids, transfusion, pain control); if intervention is necessary, angiographic embolization is an option in hemodynamically stable patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15371703\">",
"    <span class=\"h3\">",
"     Pain in the lower abdomen",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15371987\">",
"    <span class=\"h4\">",
"     Acute appendicitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appendicitis is the most common cause of the acute surgical abdomen during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/36\">",
"     36",
"    </a>",
"    ]. The most common symptom of appendicitis, ie, right lower quadrant pain, occurs within a few centimeters of McBurney's point in the vast majority of pregnant women, regardless of the stage of pregnancy. The clinical diagnosis should be strongly suspected in pregnant women with classic findings: abdominal pain that migrates to the right lower quadrant, right lower quadrant tenderness,",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    fever, and leukocytosis with left shift. With a nonclassical presentation, which often happens in pregnancy, imaging is indicated. Graded compression ultrasonography is the first-line modality. The primary goal of imaging is to reduce delays in surgical intervention due to diagnostic uncertainty. A secondary goal is to reduce, but not eliminate, the negative appendectomy rate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/34/42536?source=see_link\">",
"     \"Acute appendicitis in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15372038\">",
"    <span class=\"h4\">",
"     Nephrolithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected patients usually present in the second or third trimester (approximately 20 percent in the first trimester) with acute flank pain (90 percent), which often radiates to the groin or lower abdomen; hematuria is present in 75 to 95 percent, one-third of whom have gross hematuria and 40 percent have pyuria. Fever is present if there is an accompanying upper urinary tract infection. When diagnostic ultrasound is performed, physiological hydronephrosis of pregnancy must be distinguished from pathological hydronephrosis from obstruction. Transvaginal ultrasonography should be performed in women in whom transabdominal ultrasonography is not informative, and can help detect distal ureteral stones. Further options, when needed, include MR urography or low dose CT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38340?source=see_link\">",
"     \"Nephrolithiasis during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15372268\">",
"    <span class=\"h4\">",
"     Inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pain of inflammatory bowel disease is crampy and associated with changes in bowel movements (loose, bloody, mucousy). Pain ranges from mild to severe and positively correlates with other bowel symptoms. Fever and weight loss occur in severe disease. The course of inflammatory bowel disease during pregnancy appears to be determined, in part, by the activity of the disease at conception. The initial diagnosis is complicated in pregnancy, and based on endoscopic findings or imaging studies in a patient with a compatible clinical history. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/14/25834?source=see_link\">",
"     \"Fertility, pregnancy, and nursing in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15372361\">",
"    <span class=\"h4\">",
"     Diverticulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diverticulitis in pregnant women has been described in case reports; several of these cases involved Meckel's diverticulum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/37-43\">",
"     37-43",
"    </a>",
"    ]. Imaging modalities used in the diagnosis of appendicitis (ultrasonography, MR, CT) may be helpful, but a high degree of clinical suspicion and surgical intervention is usually necessary to make the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/37,43,44\">",
"     37,43,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/6/34919?source=see_link\">",
"     \"Clinical manifestations and diagnosis of colonic diverticular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15371735\">",
"    <span class=\"h3\">",
"     Diffuse abdominal pain or pain in variable locations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15372526\">",
"    <span class=\"h4\">",
"     Sickle cell crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with sickle cell disease may have abdominal pain as part of a vasoocclusive crisis. Such pain may be difficult to distinguish from an acute surgical abdomen (eg, appendicitis, cholecystitis). It is a common complication of sickle cell disease and can be difficult to distinguish from other causes of acute abdomen. Right upper quadrant symptoms are common in the setting of hepatic involvement. Approximately one-half of episodes are accompanied by objective clinical signs such as fever, swelling, tenderness, tachypnea, hypertension, nausea, and vomiting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link\">",
"     \"Overview of the clinical manifestations of sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/62/20458?source=see_link\">",
"     \"Pregnancy in women with sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/49/2842?source=see_link\">",
"     \"Hepatic manifestations of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15372582\">",
"    <span class=\"h4\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma is common in pregnancy and can lead to maternal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetal death. The initial evaluation of the pregnant trauma patient should focus on establishing maternal cardiopulmonary stability. Any treatment required to save the mother's life or treat her critical status should be undertaken, regardless of her pregnancy, including any diagnostic imaging deemed necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/2/22569?source=see_link&amp;anchor=H9#H9\">",
"     \"Trauma in pregnancy\", section on 'Evaluation and management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/2/22569?source=see_link&amp;anchor=H10#H10\">",
"     \"Trauma in pregnancy\", section on 'Assessment/stabilization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abdominal pain is a common consequence of blunt or penetrating abdominal trauma. The evaluation is similar to that in nonpregnant patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/5/19545?source=see_link\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12776?source=see_link\">",
"     \"Initial evaluation and management of abdominal stab wounds in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/54/3943?source=see_link\">",
"     \"Initial evaluation and management of abdominal gunshot wounds in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once catastrophic trauma has been excluded, the physician should determine whether the patient has any obstetric complications (eg, abruption, uterine rupture, fetomaternal hemorrhage, preterm labor, premature rupture of membranes). The majority of women who develop adverse obstetrical outcomes have symptoms such as contractions, vaginal bleeding, or abdominal pain upon initial presentation, but some may have minimal symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/2/22569?source=see_link\">",
"     \"Trauma in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h4\">",
"     Gastroenteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe maternal abdominal pain suggestive of abruption has been reported in association with maternal enterovirus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Other types of gastroenteritis and mesenteric adenitis also may cause an acute abdomen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=see_link&amp;anchor=H685316126#H685316126\">",
"     \"Differential diagnosis of abdominal pain in adults\", section on 'Mesenteric lymphadenitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=see_link&amp;anchor=H43#H43\">",
"     \"Differential diagnosis of abdominal pain in adults\", section on 'Eosinophilic gastroenteritis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1853906819\">",
"    <span class=\"h4\">",
"     Mesenteric venous thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesenteric vein thrombi can lead to bowel edema and, if arterial inflow becomes impaired, bowel infarction. The clinical presentation is characterized by insidious onset of poorly localized abdominal pain, which may be accompanied by nausea, vomiting, and abdominal distention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/47\">",
"     47",
"    </a>",
"    ]. It has been described in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]; risk factors include hypercoagulable states, portal hypertension, abdominal infections, blunt abdominal trauma, pancreatitis, splenectomy, and malignancy in the portal region. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44377?source=see_link&amp;anchor=H12#H12\">",
"     \"Acute mesenteric ischemia\", section on 'Mesenteric venous thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8778758\">",
"    <span class=\"h4\">",
"     Iliopsoas abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abscess of the psoas muscle is a rare cause of abdominal pain in pregnancy or postpartum and has only been described in case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Patients usually present with vague findings including back pain, difficulty with ambulation, weight loss, and malaise. Diagnosis requires a high clinical suspicion in a patient with a history of intravenous drug use. Physical examination findings may include fever, costovertebral angle tenderness, lower back tenderness, or a mass in the groin. CT or MR imaging may help to diagnose the abscess and guide treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/19/22839?source=see_link\">",
"     \"Psoas abscess\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2684089\">",
"    <span class=\"h4\">",
"     Abdominal wall pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior cutaneous nerve entrapment syndrome (ACNES) typically causes chronic abdominal wall pain. On physical examination, the patient is able to point with one finger to the area of maximal tenderness and may display the \"hover sign,\" referring to patients who guard the affected area from the examiner's hands. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=see_link&amp;anchor=H41#H41\">",
"     \"Differential diagnosis of abdominal pain in adults\", section on 'Abdominal wall pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10099204\">",
"    <span class=\"h4\">",
"     Abdominal wall hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal hernias may present with pain, bulging, or both. If severe, there may be signs of bowel obstruction. Abdominal hernias develop as a result of prior surgery (incisional) or spontaneously (umbilical, epigastric, Spigelian, or lumbar hernias). Presentation depends on the type and location of the hernia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43801?source=see_link\">",
"     \"Overview of abdominal hernias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2684168\">",
"    <span class=\"h4\">",
"     Hereditary angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary angioedema (HAE) is characterized clinically by recurrent episodes of angioedema, without accompanying hives or pruritus, which most commonly affect the skin, upper airway, or bowel. Bowel edema manifests as varying degrees of gastrointestinal colic, nausea, vomiting,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diarrhea. One-third of women experience exacerbation of symptoms during pregnancy. Ultrasonography is useful for evaluation of gastrointestinal attacks of HAE. The most common early finding is bowel wall edema, although this may resolve rapidly. Ascites may be the only finding during later stages of the attack. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19272?source=see_link\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33864?source=see_link\">",
"     \"Hereditary angioedema: Pathogenesis and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Gynecologic causes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27312329\">",
"    <span class=\"h3\">",
"     Ovarian torsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of ovarian torsion is similar in pregnant and nonpregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/53\">",
"     53",
"    </a>",
"    ]. It typically presents with lateralized lower abdominal pain, frequently accompanied by nausea, vomiting, low grade fever,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    leukocytosis. It occurs in all three trimesters, but is most common in the first trimester. Risk factors include the presence of an ovarian cyst or mass and induction of ovulation, which can cause enlarged multicystic ovaries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A presumptive diagnosis of torsion can be made with a fair degree of confidence in the presence of acute pelvic pain and an adnexal mass with a sonographic appearance (including Doppler studies) consistent with torsion and after exclusion of other conditions. A definitive diagnosis requires direct visualization of a rotated ovary at the time of surgery for evaluation and treatment (untwisting of the ovary). In one study, 7 of 41 pregnant women who underwent untwisting of the ovary had recurrent torsion in the same pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23690?source=see_link\">",
"     \"Ovarian and fallopian tube torsion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21566288\">",
"    <span class=\"h3\">",
"     Ruptured or hemorrhagic ovarian cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rupture of an ovarian cyst (eg, corpus luteum cyst) or hemorrhage into an ovarian cyst may be associated with the sudden onset of unilateral lower abdominal pain. The pain often begins during strenuous physical activity, such as exercise or sexual intercourse. Rupture may be accompanied by severe bleeding into the pelvis and hemodynamic instability. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/40/9863?source=see_link\">",
"     \"Evaluation and management of ruptured ovarian cyst\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ultrasound is the first-line imaging study for identification and characterization of the ovarian",
"    <span class=\"nowrap\">",
"     mass/cyst,",
"    </span>",
"    and to look for fluid in the cul-de-sac. The management of an ovarian neoplasm detected during pregnancy depends on its ultrasonographic characteristics and whether there are associated symptoms. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Fibroid degeneration or torsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of fibroids remain asymptomatic in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Degeneration may occur, and is more common with leiomyomas &gt;5 cm in diameter. Most patients have only localized pain, although mild leukocytosis, fever, peritoneal signs, and nausea and vomiting can occur. Pedunculated fibroids are at risk of torsion; symptoms are similar to those with degeneration. Fibroids are readily identified on ultrasound examination. Pain after ballottement by the abdominal ultrasound probe directly over the fibroid supports the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/45/15065?source=see_link\">",
"     \"Pregnancy in women with uterine leiomyomas (fibroids)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6426?source=see_link&amp;anchor=H5287062#H5287062\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Leiomyoma degeneration or torsion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Pelvic inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic inflammatory disease (PID) is extremely rare during pregnancy because the cervical mucous plug and decidua form a barrier that protects the uterus from ascending bacteria. Other diagnoses should be considered before PID in pregnant women with fever and lower abdominal pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Postpartum abdominal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Midline, intermittent, lower abdominal and back pain are common postpartum and believed to be due to hypertonic uterine contractions. Typically, the pain is exacerbated by breastfeeding and is worse in multiparas than primiparas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. The pain usually resolves by the end of the first postpartum week. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39402?source=see_link&amp;anchor=H26#H26\">",
"     \"Overview of postpartum care\", section on 'Pain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any of the causes of abdominal pain and acute abdomen discussed above can occur in the postpartum woman, as well (",
"    <a class=\"graphic graphic_table graphicRef54003 \" href=\"mobipreview.htm?7/20/7500\">",
"     table 4",
"    </a>",
"    ). Pathologic causes of pain particularly associated with the postpartum period include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Endometritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of postpartum endometritis is largely based upon clinical criteria of fever and uterine tenderness occurring in a postpartum woman. Other signs and symptoms which support the diagnosis include malodorous lochia, chills, and lower abdominal pain. The uterus may be soft and subinvoluted, which can lead to excessive uterine bleeding. Sepsis is an unusual presentation. Most cases develop after cesarean delivery and within the first week after birth, but 15 percent present between one and six weeks postpartum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39097?source=see_link\">",
"     \"Postpartum endometritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Incisional complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications related to an incision for cesarean delivery are a common cause of abdominal wall pain and include hematomas, seromas, infection, and dehiscence. The diagnosis is based on characteristic findings on physical examination, with ultrasound of the abdominal wall in cases of diagnostic uncertainty. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/39/21113?source=see_link\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Necrotizing fasciitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unexplained pain, which increases rapidly over time, may be the first manifestation of necrotizing fasciitis. Erythema may be present diffusely or locally, but in some patients, excruciating pain in the absence of any cutaneous findings is the only clue to the infection. In addition to pain and skin findings, fever, malaise, myalgias, diarrhea, and anorexia may also be present during the first 24 hours. The development of anesthesia may precede the appearance of skin necrosis and provide a clue that the process is necrotizing fasciitis rather than cellulitis.",
"   </p>",
"   <p>",
"    It is important to consider this diagnosis in the setting of fever, toxicity, soft tissue involvement with severe pain (out of proportion to skin findings in some cases), crepitus, rapid progression of clinical manifestations, and elevated serum creatine&nbsp;kinase level. Blood cultures should be obtained, but the diagnosis is established surgically. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Ovarian vein thrombophlebitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with ovarian vein thrombophlebitis (OVT) usually present within one week after delivery. They appear clinically ill; symptoms may include fever and abdominal pain localized to the side of the affected vein, the flank, or the back. The right ovarian vein is more commonly involved than the left (80 versus 6 percent); bilateral involvement occurs in 14 percent of cases. Pelvic tenderness may reflect OVT or an alternative diagnosis such as endometritis. Nausea, ileus, and other gastrointestinal symptoms may occur, but are usually mild, which may be helpful in distinguishing right-sided OVT from appendicitis, pyelonephritis, or other processes. Although much less common, other pelvic vessels may develop thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/41/6807?source=see_link&amp;anchor=H4#H4\">",
"     \"Septic pelvic thrombophlebitis\", section on 'Ovarian vein thrombophlebitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with deep septic pelvic thrombophlebitis usually present with fever in the early postpartum period (usually within three to five days), although the onset may be delayed to up to three weeks following delivery. Patients usually do not appear clinically ill; fever or chills may be the only symptoms. Abdominal or pelvic tenderness is notably absent, which helps to distinguish this disorder from OVT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/41/6807?source=see_link\">",
"     \"Septic pelvic thrombophlebitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Imaging should be obtained to evaluate the pelvic vessels and for other potential processes. CT is the preferred diagnostic modality but MR is acceptable; ultrasonography is not very useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     C. difficile diarrhea with colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of C. difficile-associated diarrhea with colitis may be increasing in postpartum women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Manifestations of the disease include watery diarrhea up to 10 or 15 times daily with lower abdominal pain cramping, low grade fever, and leukocytosis. These symptoms generally occur in the setting of recent antibiotic administration. The diagnosis is based on results from a laboratory diagnostic test detecting toxin-producing strains (via enzyme immunoassay or polymerase chain reaction) or an endoscopic evaluation that demonstrates pseudomembranes in the colon. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Urinary retention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal birth (especially forceps-assisted) and cesarean delivery have been associated with postpartum urinary retention. The excessively enlarged bladder can be palpated abdominally. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39402?source=see_link&amp;anchor=H29#H29\">",
"     \"Overview of postpartum care\", section on 'Voiding difficulty and urinary retention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraabdominal or retroperitoneal hemorrhage may be associated with abdominal pain, but more commonly manifests as hemodynamic instability (tachycardia, hypotension, or shock). Hemorrhage may be related to injury to a blood vessel at cesarean delivery or uterine rupture during delivery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=see_link\">",
"     \"Overview of postpartum hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/4/16455?source=see_link\">",
"     \"Management of hematomas incurred as a result of obstetrical delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Adynamic ileus and acute colonic pseudoobstruction (Ogilvie's syndrome)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal pain with distension, nausea, and possibly vomiting characterizes these disorders, which are more likely to occur after cesarean than vaginal delivery. The diagnosis can be made only after excluding the presence of toxic megacolon or mechanical obstruction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2586?source=see_link\">",
"     \"Postoperative ileus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22311?source=see_link\">",
"     \"Acute colonic pseudo-obstruction (Ogilvie's syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Hepatic distension and rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic manifestations of severe preeclampsia, HELLP syndrome, and acute fatty liver may develop or be first recognized postpartum. (See",
"    <a class=\"local\" href=\"#H21566339\">",
"     'Pregnancy-related liver disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2684122\">",
"    <span class=\"h3\">",
"     Abdominal compartment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal compartment syndrome should be considered when severe abdominal pain with abdominal distension occurs in women with unusual abdominal pain postcesarean delivery. The syndrome is lethal if not diagnosed early. Findings noted on CT imaging are bowel wall thickening, elevated diaphragm, and collapse of the inferior vena cava along with mucosal hyperenhancement and hemoperitoneum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20761?source=see_link\">",
"     \"Abdominal compartment syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Pubic symphysis separation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of pubic symphysis separation include suprapubic pain, tenderness, swelling, and edema with pain radiating to the legs, hips, or back. The pain often increases with weight bearing, especially with walking and climbing stairs. Turning in bed, lifting, or getting up from a chair may also cause pain. Some women report waking up during the night because of pain. The diagnosis is based on characteristic symptoms and physical examination: pain evoked by bilateral pressure on the trochanters or by hip flexion with the legs in extension. Rarely, a palpable groove at the level of the symphysis may be detected by internal or external examination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/1/2074?source=see_link&amp;anchor=H14#H14\">",
"     \"Musculoskeletal changes and pain during pregnancy and postpartum\", section on 'Pelvic girdle pain'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/1/2074?source=see_link&amp;anchor=H13#H13\">",
"     \"Musculoskeletal changes and pain during pregnancy and postpartum\", section on 'Pubic symphysis separation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Foreign body",
"    </span>",
"    &nbsp;&mdash;&nbsp;After cesarean delivery, the possibility of a retained instrument or gauze sponge should be considered in patients with symptoms such as nonspecific abdominal pain, fever, nausea, and vomiting. However, the presentation is often years after the surgery. The diagnosis is made radiographically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Unrecognized visceral injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;An unrecognized injury to the genitourinary or gastrointestinal system that occurred during a cesarean delivery or postpartum sterilization procedure could lead to postpartum peritonitis, bowel obstruction, or bowel ischemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42617?source=see_link&amp;anchor=H8#H8\">",
"     \"Anaerobic bacterial infections\", section on 'Intraabdominal infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Intraabdominal or pelvic abscess, surgical soft tissue infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic abscess in women is usually a complication of PID, but can also follow pelvic surgery or be related to non-gynecological, non-obstetrical conditions such as urological surgery, gastrointestinal surgery, or gastrointestinal disease (eg, inflammatory bowel disease). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36823?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/50/4906?source=see_link\">",
"     \"Surgical management of ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Group A streptococcal infection (GAS) is an uncommon, but frequently life-threatening infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Clinical manifestations of GAS bacteremia include those of the primary site of infection and of the bacteremia. Deep soft tissue infections, such as myonecrosis or necrotizing fasciitis (see",
"    <a class=\"local\" href=\"#H34\">",
"     'Necrotizing fasciitis'",
"    </a>",
"    above), and postpartum infection are frequently associated with bacteremia, shock, and organ failure.",
"   </p>",
"   <p>",
"    Abdominal pain begins 24 to 48 hours following vaginal or cesarean delivery, and continues to worsen. Petechiae, ecchymoses, and digital embolization may occur with subsequent evidence of thrombocytopenia and disseminated intravascular coagulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42551?source=see_link\">",
"     \"Group A streptococcal (Streptococcus pyogenes) bacteremia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H911398\">",
"    <span class=\"h3\">",
"     Myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial infarction (MI) is rare in women of childbearing age, although the risk is increased in the third trimester and the early postpartum period. Risk factors include the traditional coronary heart disease risk factors, particularly maternal age over 35 years, diabetes mellitus, hypertension, smoking, thrombophilia, postpartum hemorrhage, and postpartum infection. In a review of 103 cases from 1995 to 2005, coronary artery morphology was evaluated in 96 by arteriography or autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/66\">",
"     66",
"    </a>",
"    ]. Coronary atherosclerosis with or without intracoronary thrombus was present in only 40 percent. The remaining cases consisted of coronary artery dissection (27 percent), thrombus in a normal coronary artery (8 percent), spasm (2 percent), emboli (2 percent), and normal coronary arteries (13 percent). Atherosclerosis is more common with antepartum MI, while coronary dissection is more common peripartum and postpartum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/44/36554/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]. The diagnosis of acute MI is mostly guided by the same principles as in the general population, including ischemic symptoms (eg, anginal chest pain), electrocardiogram (ECG) changes, and elevations in cardiac biomarkers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30950?source=see_link\">",
"     \"Acute coronary syndromes in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/48/8962?source=see_link\">",
"       \"Patient information: Acute abdomen (belly pain) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When evaluating pregnant women with abdominal pain, the clinician needs to consider the normal",
"      <span class=\"nowrap\">",
"       physiologic/anatomic",
"      </span>",
"      alterations associated with pregnancy, gestational age and fetal well-being, and causes of abdominal",
"      <span class=\"nowrap\">",
"       pain/acute",
"      </span>",
"      abdomen that may be more common due to the pregnant state or related to obstetrical complications. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Differential diagnosis of abdominal pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although abdominal discomfort, nausea, vomiting, and constipation can be a normal part of pregnancy, the presence of peritoneal signs (rebound tenderness, abdominal guarding) is never normal in pregnant women. Nausea and vomiting are not normal manifestations of pregnancy when they occur with abdominal pain, fever, diarrhea, headache, or localized abdominal findings. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Requisite diagnostic imaging and interventions should be performed as indicated since delay in diagnosis and treatment can increase maternal and",
"      <span class=\"nowrap\">",
"       fetal/newborn",
"      </span>",
"      morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H15372999\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abdominal and pelvic ultrasound examinations are the most useful tests for evaluation of abdominal pain in pregnant women. These examinations are safe for the fetus and perform well for making and excluding most diagnoses associated with abdominal pain. When indicated, chest and abdominal plain films result in very low fetal absorption of ionizing radiation, and below doses that have been associated with short- or long-term adverse effects. Magnetic resonance imaging (MRI) does not involve ionizing radiation and thus is preferable to computed tomography (CT), which exposes the fetus to higher doses of ionizing radiation than plain films. (See",
"      <a class=\"local\" href=\"#H15373132\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/1\">",
"      Firstenberg MS, Malangoni MA. Gastrointestinal surgery during pregnancy. Gastroenterol Clin North Am 1998; 27:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/2\">",
"      Parangi S, Levine D, Henry A, et al. Surgical gastrointestinal disorders during pregnancy. Am J Surg 2007; 193:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/3\">",
"      Cormier CM, Canzoneri BJ, Lewis DF, et al. Urolithiasis in pregnancy: Current diagnosis, treatment, and pregnancy complications. Obstet Gynecol Surv 2006; 61:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/4\">",
"      Stone K. Acute abdominal emergencies associated with pregnancy. Clin Obstet Gynecol 2002; 45:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/5\">",
"      Ryan JP, Pellecchia D. Effect of ovarian hormone pretreatment on gallbladder motility in vitro. Life Sci 1982; 31:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/6\">",
"      KUVIN SF, BRECHER G. Differential neutrophil counts in pregnancy. N Engl J Med 1962; 266:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/7\">",
"      Acker DB, Johnson MP, Sachs BP, Friedman EA. The leukocyte count in labor. Am J Obstet Gynecol 1985; 153:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/8\">",
"      Baron KT, Arleo EK, Robinson C, Sanelli PC. Comparing the diagnostic performance of MRI versus CT in the evaluation of acute nontraumatic abdominal pain during pregnancy. Emerg Radiol 2012; 19:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/9\">",
"      Spalluto LB, Woodfield CA, DeBenedectis CM, Lazarus E. MR imaging evaluation of abdominal pain during pregnancy: appendicitis and other nonobstetric causes. Radiographics 2012; 32:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/10\">",
"      Beddy P, Keogan MT, Sala E, Griffin N. Magnetic resonance imaging for the evaluation of acute abdominal pain in pregnancy. Semin Ultrasound CT MR 2010; 31:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/11\">",
"      Groen RS, Bae JY, Lim KJ. Fear of the unknown: ionizing radiation exposure during pregnancy. Am J Obstet Gynecol 2012; 206:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/12\">",
"      Brosens IA, Fusi L, Brosens JJ. Endometriosis is a risk factor for spontaneous hemoperitoneum during pregnancy. Fertil Steril 2009; 92:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/13\">",
"      Bloom SL, Uppot R, Roberts DJ. Case records of the Massachusetts General Hospital. Case 32-2010. A pregnant woman with abdominal pain and fluid in the peritoneal cavity. N Engl J Med 2010; 363:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/14\">",
"      Fiori O, Prugnolles H, Darai E, et al. Spontaneous uterine artery rupture during pregnancy in a woman with sickle cell disease: a case report. J Reprod Med 2007; 52:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/15\">",
"      Swaegers MC, Hauspy JJ, Buytaert PM, De Maeseneer MG. Spontaneous rupture of the uterine artery in pregnancy. Eur J Obstet Gynecol Reprod Biol 1997; 75:145.",
"     </a>",
"    </li>",
"    <li>",
"     Ellman, JS. Spontaneous rupture of a branch of the uterine artery in the third trimester of pregnancy. Obstet Gynecol 1963; 21:75",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/17\">",
"      Practice Committee of American Society For Reproductive Medicine. Increased maternal cardiovascular mortality associated with pregnancy in women with Turner syndrome. Fertil Steril 2012; 97:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/18\">",
"      la Chapelle CF, Schutte JM, Schuitemaker NW, et al. Maternal mortality attributable to vascular dissection and rupture in the Netherlands: a nationwide confidential enquiry. BJOG 2012; 119:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/19\">",
"      Chao LW, Chen CH. Spontaneous rupture of an ovarian artery aneurysm: case report and review of the literature. Gynecol Obstet Invest 2009; 68:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/20\">",
"      Ramin KD, Ramin SM, Richey SD, Cunningham FG. Acute pancreatitis in pregnancy. Am J Obstet Gynecol 1995; 173:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/21\">",
"      Papadakis EP, Sarigianni M, Mikhailidis DP, et al. Acute pancreatitis in pregnancy: an overview. Eur J Obstet Gynecol Reprod Biol 2011; 159:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/22\">",
"      Karsenti D, Bacq Y, Br&eacute;chot JF, et al. Serum amylase and lipase activities in normal pregnancy: a prospective case-control study. Am J Gastroenterol 2001; 96:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/23\">",
"      Ordorica SA, Frieden FJ, Marks F, et al. Pancreatic enzyme activity in pregnancy. J Reprod Med 1991; 36:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/24\">",
"      Kaiser R, Berk JE, Fridhandler L. Serum amylase changes during pregnancy. Am J Obstet Gynecol 1975; 122:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/25\">",
"      Xydas NP, May JH, Henson MC. Maternal serum amylase and lipase profiles in pregnancy: determinations in both once-sampled and multisampled patient cohorts. South Med J 1996; 89:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/26\">",
"      Kakarla N, Dailey C, Marino T, et al. Pregnancy after gastric bypass surgery and internal hernia formation. Obstet Gynecol 2005; 105:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/27\">",
"      Pratt AT, Donaldson RC, Evertson LR, Yon JL Jr. Cecal volvulus in pregnancy. Obstet Gynecol 1981; 57:37S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/28\">",
"      Essilfie P, Hussain M, Bolaji I. Perforated duodenal ulcer in pregnancy-a rare cause of acute abdominal pain in pregnancy: a case report and literature review. Case Rep Obstet Gynecol 2011; 2011:263016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/29\">",
"      Mattar SG, Lumsden AB. The management of splenic artery aneurysms: experience with 23 cases. Am J Surg 1995; 169:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/30\">",
"      Hillemanns P, Knitza R, M&uuml;ller-H&ouml;cker J. Rupture of splenic artery aneurysm in a pregnant patient with portal hypertension. Am J Obstet Gynecol 1996; 174:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/31\">",
"      Messina LM, Shanley CJ. Visceral artery aneurysms. Surg Clin North Am 1997; 77:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/32\">",
"      Selo-Ojeme DO, Welch CC. Review: spontaneous rupture of splenic artery aneurysm in pregnancy. Eur J Obstet Gynecol Reprod Biol 2003; 109:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/33\">",
"      Sadat U, Dar O, Walsh S, Varty K. Splenic artery aneurysms in pregnancy--a systematic review. Int J Surg 2008; 6:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/34\">",
"      Karmazyn B, Steinberg R, Gayer G, et al. Wandering spleen--the challenge of ultrasound diagnosis: report of 7 cases. J Clin Ultrasound 2005; 33:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/35\">",
"      Tolcher MC, Nitsche JF, Arendt KW, Rose CH. Spontaneous rectus sheath hematoma pregnancy: case report and review of the literature. Obstet Gynecol Surv 2010; 65:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/36\">",
"      Tamir IL, Bongard FS, Klein SR. Acute appendicitis in the pregnant patient. Am J Surg 1990; 160:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/37\">",
"      Huerta S, Barleben A, Peck MA, Gordon IL. Meckel's diverticulitis: a rare etiology of an acute abdomen during pregnancy. Curr Surg 2006; 63:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/38\">",
"      Ragu N, Tichoux C, Bouyabrine H, et al. [Complicated diverticulitis during pregnancy]. J Radiol 2004; 85:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/39\">",
"      Bodner J, Windisch J, Bale R, et al. Perforated right colonic diverticulitis complicating pregnancy at 37 weeks' gestation. Int J Colorectal Dis 2005; 20:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/40\">",
"      Chanrachakul B, Tangtrakul S, Herabutya Y, et al. Meckel's diverticulitis: an uncommon complication during pregnancy. BJOG 2001; 108:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/41\">",
"      Sherer DM, Frager D, Eliakim R. An unusual case of diverticulitis complicating pregnancy at 33 weeks' gestation. Am J Perinatol 2001; 18:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/42\">",
"      Pelosi MA 3rd, Pelosi MA, Villalona E. Right-sided colonic diverticulitis mimicking acute cholecystitis in pregnancy: case report and laparoscopic treatment. Surg Laparosc Endosc 1999; 9:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/43\">",
"      Wong YS, Liu SY, Ng SS, et al. Giant Meckel's diverticulitis: a rare condition complicating pregnancy. Am J Surg 2010; 200:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/44\">",
"      Longo SA, Moore RC, Canzoneri BJ, Robichaux A. Gastrointestinal Conditions during Pregnancy. Clin Colon Rectal Surg 2010; 23:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/45\">",
"      Johansson ME, Holmstr&ouml;m S, Abebe A, et al. Intrauterine fetal death due to echovirus 11. Scand J Infect Dis 1992; 24:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/46\">",
"      Modlin JF. Fatal echovirus 11 disease in premature neonates. Pediatrics 1980; 66:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/47\">",
"      Woodfield CA, Lazarus E, Chen KC, Mayo-Smith WW. Abdominal pain in pregnancy: diagnoses and imaging unique to pregnancy--review. AJR Am J Roentgenol 2010; 194:WS14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/48\">",
"      Atakan Al R, Borekci B, Ozturk G, et al. Acute mesenteric venous thrombosis due to protein S deficiency in a pregnant woman. J Obstet Gynaecol Res 2009; 35:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/49\">",
"      Engelhardt TC, Kerstein MD. Pregnancy and mesenteric venous thrombosis. South Med J 1989; 82:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/50\">",
"      Nelson DB, Manders DB, Shivvers SA. Primary iliopsoas abscess and pregnancy. Obstet Gynecol 2010; 116 Suppl 2:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/51\">",
"      Young OM, Werner E, Sfakianaki AK. Primary psoas muscle abscess after an uncomplicated spontaneous vaginal delivery. Obstet Gynecol 2010; 116 Suppl 2:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/52\">",
"      Delke I. Psoas abscess in obstetrics: uncommon condition with common presentations. Obstet Gynecol 2010; 116 Suppl 2:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/53\">",
"      Hasson J, Tsafrir Z, Azem F, et al. Comparison of adnexal torsion between pregnant and nonpregnant women. Am J Obstet Gynecol 2010; 202:536.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/54\">",
"      Smorgick N, Pansky M, Feingold M, et al. The clinical characteristics and sonographic findings of maternal ovarian torsion in pregnancy. Fertil Steril 2009; 92:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/55\">",
"      Strobelt N, Ghidini A, Cavallone M, et al. Natural history of uterine leiomyomas in pregnancy. J Ultrasound Med 1994; 13:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/56\">",
"      Aharoni A, Reiter A, Golan D, et al. Patterns of growth of uterine leiomyomas during pregnancy. A prospective longitudinal study. Br J Obstet Gynaecol 1988; 95:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/57\">",
"      Neiger R, Sonek JD, Croom CS, Ventolini G. Pregnancy-related changes in the size of uterine leiomyomas. J Reprod Med 2006; 51:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/58\">",
"      Murray A, Holdcroft A. Incidence and intensity of postpartum lower abdominal pain. BMJ 1989; 298:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/59\">",
"      Holdcroft A, Snidvongs S, Cason A, et al. Pain and uterine contractions during breast feeding in the immediate post-partum period increase with parity. Pain 2003; 104:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/60\">",
"      Ducarme G, Lidove O, Leduey A, et al. Postpartum thrombosis of the superior mesenteric artery after vaginal delivery. Obstet Gynecol 2008; 111:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/61\">",
"      Garey KW, Jiang ZD, Yadav Y, et al. Peripartum Clostridium difficile infection: case series and review of the literature. Am J Obstet Gynecol 2008; 199:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/62\">",
"      Rouphael NG, O'Donnell JA, Bhatnagar J, et al. Clostridium difficile-associated diarrhea: an emerging threat to pregnant women. Am J Obstet Gynecol 2008; 198:635.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/63\">",
"      Patel A, Lall CG, Jennings SG, Sandrasegaran K. Abdominal compartment syndrome. AJR Am J Roentgenol 2007; 189:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/64\">",
"      Anteby EY, Yagel S, Hanoch J, et al. Puerperal and intrapartum group A streptococcal infection. Infect Dis Obstet Gynecol 1999; 7:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/65\">",
"      de Moya MA, del Carmen MG, Allain RM, et al. Case records of the Massachusetts General Hospital. Case 33-2009. A 35-year-old woman with fever, abdominal pain, and hypotension after cesarean section. N Engl J Med 2009; 361:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/66\">",
"      Roth A, Elkayam U. Acute myocardial infarction associated with pregnancy. J Am Coll Cardiol 2008; 52:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/67\">",
"      Koul AK, Hollander G, Moskovits N, et al. Coronary artery dissection during pregnancy and the postpartum period: two case reports and review of literature. Catheter Cardiovasc Interv 2001; 52:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/68\">",
"      Petitti DB, Sidney S, Quesenberry CP Jr, Bernstein A. Incidence of stroke and myocardial infarction in women of reproductive age. Stroke 1997; 28:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/44/36554/abstract/69\">",
"      Mather PJ, Hansen CL, Goldman B, et al. Postpartum multivessel coronary dissection. J Heart Lung Transplant 1994; 13:533.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4807 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-41.196.66.12-D2B050E0E1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_44_36554=[""].join("\n");
var outline_f35_44_36554=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H46\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15372999\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15373475\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15373027\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15373132\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2678326\">",
"      - Ionizing radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15373161\">",
"      Laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIFFERENTIAL DIAGNOSIS OF ABDOMINAL PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pregnancy-related causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2677824\">",
"      - First half of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1853906811\">",
"      Miscarriage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Extrauterine (ectopic) pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2677879\">",
"      - Second half of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2677706\">",
"      Labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2677794\">",
"      Placental abruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2677735\">",
"      Uterine rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21566339\">",
"      Pregnancy-related liver disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Severe preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H21566370\">",
"      - HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Acute fatty liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21566319\">",
"      Intraamniotic infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2682620\">",
"      Spontaneous hemoperitoneum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4870065\">",
"      Uterine incarceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2682683\">",
"      Arterial dissection and rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nonpregnancy-related causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15371695\">",
"      - Pain in the upper abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2683327\">",
"      Gastroesophageal reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15371778\">",
"      Gallbladder disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15371809\">",
"      Acute hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15371889\">",
"      Pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15371940\">",
"      Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15372127\">",
"      Bowel obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15372490\">",
"      Perforated ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15372650\">",
"      Disorders of the spleen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15373413\">",
"      Hiatal hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1057508\">",
"      Rectus sheath hematoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15371703\">",
"      - Pain in the lower abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15371987\">",
"      Acute appendicitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15372038\">",
"      Nephrolithiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15372268\">",
"      Inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15372361\">",
"      Diverticulitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15371735\">",
"      - Diffuse abdominal pain or pain in variable locations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15372526\">",
"      Sickle cell crisis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15372582\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1853906819\">",
"      Mesenteric venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8778758\">",
"      Iliopsoas abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2684089\">",
"      Abdominal wall pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10099204\">",
"      Abdominal wall hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2684168\">",
"      Hereditary angioedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Gynecologic causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27312329\">",
"      - Ovarian torsion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21566288\">",
"      - Ruptured or hemorrhagic ovarian cyst",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Fibroid degeneration or torsion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Postpartum abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Endometritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Incisional complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Necrotizing fasciitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Ovarian vein thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - C. difficile diarrhea with colitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Urinary retention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Adynamic ileus and acute colonic pseudoobstruction (Ogilvie's syndrome)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Hepatic distension and rupture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2684122\">",
"      - Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Pubic symphysis separation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Foreign body",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Unrecognized visceral injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Intraabdominal or pelvic abscess, surgical soft tissue infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H911398\">",
"      - Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4807\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4807|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/14/12514\" title=\"figure 1\">",
"      Liver disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/54/24419\" title=\"figure 2\">",
"      Patterns of referred abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4807|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/33/38424\" title=\"table 1\">",
"      Normal reference ranges in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/31/4603\" title=\"table 2A\">",
"      Criteria for preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/60/43979\" title=\"table 2B\">",
"      Criteria for severe preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/9/19613\" title=\"table 3A\">",
"      Causes of abdominal pain by location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/4/12365\" title=\"table 3B\">",
"      Extra-abdominal causes abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/20/7500\" title=\"table 4\">",
"      Causes postpartum pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20761?source=related_link\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/4/16457?source=related_link\">",
"      Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/39/21113?source=related_link\">",
"      Abdominal surgical incisions: Prevention and treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/34/42536?source=related_link\">",
"      Acute appendicitis in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22311?source=related_link\">",
"      Acute colonic pseudo-obstruction (Ogilvie's syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30950?source=related_link\">",
"      Acute coronary syndromes in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24166?source=related_link\">",
"      Acute fatty liver of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33479?source=related_link\">",
"      Acute kidney injury (acute renal failure) in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44377?source=related_link\">",
"      Acute mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42617?source=related_link\">",
"      Anaerobic bacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2232?source=related_link\">",
"      Antepartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26198?source=related_link\">",
"      Approach to liver disease occurring during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16120?source=related_link\">",
"      Approach to the adult with nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=related_link\">",
"      Approach to the patient with an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8663?source=related_link\">",
"      Cecal volvulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5290?source=related_link\">",
"      Choosing the route of delivery after cesarean birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41207?source=related_link\">",
"      Clinical features and evaluation of nausea and vomiting of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/6/34919?source=related_link\">",
"      Clinical manifestations and diagnosis of colonic diverticular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44808?source=related_link\">",
"      Clinical manifestations and diagnosis of early pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/41/13976?source=related_link\">",
"      ERCP in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36823?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/40/9863?source=related_link\">",
"      Evaluation and management of ruptured ovarian cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/44/17095?source=related_link\">",
"      Evaluation of acute pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27945?source=related_link\">",
"      Fertility and pregnancy after bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/14/25834?source=related_link\">",
"      Fertility, pregnancy, and nursing in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28201?source=related_link\">",
"      Gallstone disease in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42551?source=related_link\">",
"      Group A streptococcal (Streptococcus pyogenes) bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21703?source=related_link\">",
"      Hematologic changes in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/49/2842?source=related_link\">",
"      Hepatic manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19272?source=related_link\">",
"      Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33864?source=related_link\">",
"      Hereditary angioedema: Pathogenesis and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/22/7527?source=related_link\">",
"      Hiatus hernia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/24/40323?source=related_link\">",
"      History and physical examination in adults with abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21334?source=related_link\">",
"      Incarcerated gravid uterus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/54/3943?source=related_link\">",
"      Initial evaluation and management of abdominal gunshot wounds in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12776?source=related_link\">",
"      Initial evaluation and management of abdominal stab wounds in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/5/19545?source=related_link\">",
"      Initial evaluation and management of blunt abdominal trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/24/14726?source=related_link\">",
"      Intercurrent hepatobiliary disease during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42761?source=related_link\">",
"      Intraamniotic infection (chorioamnionitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8727?source=related_link\">",
"      Laparoscopic surgery in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/4/16455?source=related_link\">",
"      Management of hematomas incurred as a result of obstetrical delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15482?source=related_link\">",
"      Management of pregnant women undergoing nonobstetric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9160?source=related_link\">",
"      Maternal gastrointestinal tract adaptation to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44565?source=related_link\">",
"      Mirizzi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/1/2074?source=related_link\">",
"      Musculoskeletal changes and pain during pregnancy and postpartum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38340?source=related_link\">",
"      Nephrolithiasis during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/7/14454?source=related_link\">",
"      Normal reference ranges for laboratory values in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23690?source=related_link\">",
"      Ovarian and fallopian tube torsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43801?source=related_link\">",
"      Overview of abdominal hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/26/30121?source=related_link\">",
"      Overview of fetal assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39402?source=related_link\">",
"      Overview of postpartum care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=related_link\">",
"      Overview of postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/30/5608?source=related_link\">",
"      Overview of preterm labor and birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/21/40282?source=related_link\">",
"      Overview of the complications of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/6/15465?source=related_link\">",
"      Overview of the etiology and evaluation of vaginal bleeding in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/48/8962?source=related_link\">",
"      Patient information: Acute abdomen (belly pain) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34663?source=related_link\">",
"      Placental abruption: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2586?source=related_link\">",
"      Postoperative ileus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39097?source=related_link\">",
"      Postpartum endometritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/62/20458?source=related_link\">",
"      Pregnancy in women with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/45/15065?source=related_link\">",
"      Pregnancy in women with uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/19/22839?source=related_link\">",
"      Psoas abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/4/44102?source=related_link\">",
"      Rupture of the unscarred uterus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/41/6807?source=related_link\">",
"      Septic pelvic thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26453?source=related_link\">",
"      Sigmoid volvulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14058?source=related_link\">",
"      Small bowel obstruction: Causes and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8807?source=related_link\">",
"      Small bowel obstruction: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/23/19834?source=related_link\">",
"      Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/50/4906?source=related_link\">",
"      Surgical management of ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/2/22569?source=related_link\">",
"      Trauma in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36344?source=related_link\">",
"      Treatment of respiratory infections in pregnant women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_44_36555="BAL connective tissue disease";
var content_f35_44_36555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bronchoalveolar lavage cytology in connective tissue disease with and without associated interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        With ILD",
"       </td>",
"       <td class=\"subtitle1\">",
"        Without ILD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progressive systemic sclerosis",
"       </td>",
"       <td>",
"        Neutrophils,",
"eosinophils",
"       </td>",
"       <td>",
"        Neutrophils, eosinophils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid arthritis",
"       </td>",
"       <td>",
"        Neutrophils,",
"lymphocytes",
"       </td>",
"       <td>",
"        Lymphocytes (CD4+, T5/9)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary Sj&ouml;gren's syndrome",
"       </td>",
"       <td>",
"        Neutrophils,",
"lymphocytes (CD8+)",
"       </td>",
"       <td>",
"        Lymphocytes (CD4+)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus",
"       </td>",
"       <td>",
"        Neutrophils,",
"lymphocytes",
"       </td>",
"       <td>",
"        Lymphocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatopolymyositis",
"       </td>",
"       <td>",
"        Neutrophils",
"       </td>",
"       <td>",
"        Neutrophils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mixed",
"connective tissue disease",
"       </td>",
"       <td>",
"        Neutrophils",
"       </td>",
"       <td>",
"        Neutrophils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Secondary",
"Sj&ouml;gren's syndrome",
"       </td>",
"       <td>",
"        Neutrophils,",
"lymphocytes (CD8+)",
"       </td>",
"       <td>",
"        Neutrophils, lymphocytes (CD8+)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Presence of interstitial lung disease&nbsp;(ILD) is judged by clinical and radiographic findings.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Wallaert B, Rossi GA, Sibille Y, Eur Respir J 1990; 3:942.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_44_36555=[""].join("\n");
var outline_f35_44_36555=null;
var title_f35_44_36556="Early vs late diver comps";
var content_f35_44_36556=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Early versus late complications in continent urinary diversions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Complication type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Early (within 30 days)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Long term (30 days to death)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Reservoir-related",
"       </td>",
"       <td>",
"        Urinary leak",
"       </td>",
"       <td>",
"        1.8-10",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyleonephritis",
"       </td>",
"       <td>",
"        0.9-13",
"       </td>",
"       <td>",
"        Pyleonephritis",
"       </td>",
"       <td>",
"        3-10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Upper tract calculi",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Pouch calculi",
"       </td>",
"       <td>",
"        5-35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Anastomosis-related",
"       </td>",
"       <td>",
"        Ureteral obstruction",
"       </td>",
"       <td>",
"        0-6.3",
"       </td>",
"       <td>",
"        Ureteral obstruction/stricture",
"       </td>",
"       <td>",
"        2-30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urethral or stomal stricture",
"       </td>",
"       <td>",
"        2-14.3",
"       </td>",
"       <td>",
"        Renal deterioration",
"       </td>",
"       <td>",
"        0.4-10.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Ureteral reflux",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Bowel-related",
"       </td>",
"       <td>",
"        Fecal leak",
"       </td>",
"       <td>",
"        1-2",
"       </td>",
"       <td>",
"        Metabolic abnormalities",
"       </td>",
"       <td>",
"        15-50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged ileus",
"       </td>",
"       <td>",
"        2-11",
"       </td>",
"       <td>",
"        Bowel obstruction",
"       </td>",
"       <td>",
"        4-8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Other",
"       </td>",
"       <td>",
"        Wound infection",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wound dehiscence",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        Wound hernia",
"       </td>",
"       <td>",
"        0-10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deep venous thrombosis",
"       </td>",
"       <td>",
"        2-2.7",
"       </td>",
"       <td>",
"        Deep venous thrombosis",
"       </td>",
"       <td>",
"        0-6.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Loss of continence mechanism",
"       </td>",
"       <td>",
"        15-20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Hypercontinence (male",
"        <em>",
"         v",
"        </em>",
"        female)",
"       </td>",
"       <td>",
"        3-9",
"        <em>",
"         v",
"        </em>",
"        10-50",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_44_36556=[""].join("\n");
var outline_f35_44_36556=null;
var title_f35_44_36557="Contents: Hair and scalp disease";
var content_f35_44_36557=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?2/59/3006\">",
"       Dermatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hair and scalp disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hair and scalp disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/38/10856\">",
"           Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/46/1768\">",
"           Clinical manifestations and diagnosis of alopecia areata",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/29/9690\">",
"           Evaluation and diagnosis of hair loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/0/31752\">",
"           Female pattern hair loss (androgenetic alopecia in women): Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/0/14344\">",
"           Female pattern hair loss (androgenetic alopecia in women): Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/14/4330\">",
"           Management of alopecia areata",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/33/13846\">",
"           Nonscarring hair loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/31/36343\">",
"           Pseudofolliculitis barbae",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/50/23336\">",
"           Treatment of androgenetic alopecia in men",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-6015C9E0F8-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f35_44_36557=[""].join("\n");
var outline_f35_44_36557=null;
var title_f35_44_36558="ECF for advanced esophagogastric cancer";
var content_f35_44_36558=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Epirubicin, cisplatin, and fluorouracil (ECF) for advanced esophagogastric cancer",
"    <sup>",
"     [1,2]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 21 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Epirubicin",
"        </strong>",
"       </td>",
"       <td>",
"        50 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Administer into a free flowing IV solution with normal saline (NS)*, generally over 3 to 20 minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cisplatin",
"        </strong>",
"       </td>",
"       <td>",
"        60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 250 mL NS and administer over two hours. Do not administer with aluminum needles or intravenous sets.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day IV",
"       </td>",
"       <td>",
"        Infuse through a central line as a continuous infusion via a portable infusion device.",
"       </td>",
"       <td>",
"        Daily for up to six months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        Give IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on Prevention.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        Epirubicin plus cisplatin: HIGH; daily low-dose continuous infusion FU: LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        There are no recommended premedications to prevent infusion reactions with the ECF regimen. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Epirubicin is a vesicant; cisplatin is an irritant but can cause significant tissue damage. Avoid extravasation of either agent. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with granulocyte colony stimulating factors is not warranted (incidence of grade 3 or 4 febrile neutropenia was 9 percent in one trial",
"        <sup>",
"         [3]",
"        </sup>",
"        ; in a second trial, 14 percent developed either febrile neutropenia or infection",
"        <sup>",
"         [1]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. In the original ECF protocol, cisplatin was not given to patients with a GFR &lt;40 mL/min, full-dose cisplatin was administered to patients with a GFR &ge;60 mL/min, and if the GFR was between 40 and 60 mL/min, the dose of cisplatin (in mg) equaled the GFR value in mL/min",
"        <sup>",
"         [2]",
"        </sup>",
"        . Lower starting doses of epirubicin may be needed in patients with preexisting renal or hepatic impairment",
"        <sup>",
"         [4]",
"        </sup>",
"        . Lower starting doses of FU may be needed with severe liver impairment",
"        <sup>",
"         [5]",
"        </sup>",
"        . Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Cardiac issues:",
"        </strong>",
"        Epirubicin is associated with dose-dependent cardiomyopathy, the incidence of which is related to cumulative dose. Assess baseline LVEF prior to initiating therapy. Epirubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmias, or prior treatment with maximum cumulative doses of anthracyclines. In the original protocol, patients were excluded from receiving epirubicin if their baseline LVEF was less than 50 percent",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count on day 1 prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess basic metabolic panel including creatinine and liver function tests once per cycle on day 1 prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for neurotoxicity prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor cumulative epirubicin dose. Reassess LVEF periodically during ECF therapy as clinically indicated. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Hold epirubicin until the platelets are &ge;100,000 per mm",
"        <sup>",
"         3",
"        </sup>",
"        and the absolute neutrophil count is &ge;1500 cells/mm",
"        <sup>",
"         3[4]",
"        </sup>",
"        . In the original ECF protocol, cisplatin and epirubicin doses were delayed by one week or until myelosuppression was resolved if the platelet count was &lt;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        or the total WBC was &lt;2000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        on day 1",
"        <sup>",
"         [2]",
"        </sup>",
"        . The dose of epirubicin was reduced by 25 percent for a second episode of treatment delay due to myelosuppression or for febrile neutropenia. There were no dose reductions for infusional FU based on blood counts, but the FDA labeling recommends treatment discontinuation for neutropenia (WBC &lt;3500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        or rapidly declining) or platelet count &lt;100,000/mm",
"        <sup>",
"         3[5]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Renal dysfunction:",
"        </strong>",
"        Hold cisplatin until serum creatinine &lt;1.5 mg/dL and/or blood urea nitrogen &lt;25 mg/dL",
"        <sup>",
"         [6]",
"        </sup>",
"        . In the original trial of ECF, full dose cisplatin was given each cycle if the estimated GFR was &gt;60 mL/min, and the drug was held if the estimated GFR was &lt;40 mL/min",
"        <sup>",
"         [2]",
"        </sup>",
"        . For an estimated GFR of 40 to 60 mL/min, the dose of cisplatin (in mg) was equivalent to the estimated GFR (in mL/min)",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Mucositis or diarrhea:",
"        </strong>",
"        In the original protocol, a treatment break from FU was recommended for grade 2 or worse diarrhea. Treatment was withheld until symptoms resolved, then restarted at 150 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day for grade 2 toxicity, and at 100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day for grade 3 or 4 toxicity",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Severe diarrhea and mucositis after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurotoxicity:",
"        </strong>",
"        Neuropathy usually is seen with cumulative doses of cisplatin &gt;400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. If neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Palmar-plantar erythrodysesthesias:",
"        </strong>",
"        In the original trial, FU was withheld for one week for any grade of palmar-plantar erythrodysesthesia and then restarted at a dose of 150 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Other toxicity:",
"        </strong>",
"        Hold epirubicin until all non-hematologic toxicity resolved to &le; grade 1",
"        <sup>",
"         [4]",
"        </sup>",
"        . Reduce epirubicin dose by 25 percent for any grade 3/4 non-hematologic toxicity in previous cycles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intraveneous; GFR: glomerular filtration rate; LVEF: left ventricular ejection fraction; CBC: complete blood count; WBC: white blood cell count.",
"     <br/>",
"     * Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Webb A, et al. J Clin Oncol 1997; 15:261.",
"      </li>",
"      <li>",
"       Findlay M, et al. Ann Oncol 1994; 5:609.",
"      </li>",
"      <li>",
"       Cunningham D, et al. N Engl J Med 2008; 358:36.",
"      </li>",
"      <li>",
"       Ellence (epirubicin hydrochloride) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 6, 2011).",
"      </li>",
"      <li>",
"       Fluorouracil injection. FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 6, 2011).",
"      </li>",
"      <li>",
"       Platinol (cisplatin) injection. FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 6, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_44_36558=[""].join("\n");
var outline_f35_44_36558=null;
var title_f35_44_36559="Candida spp MICs";
var content_f35_44_36559=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    In vitro susceptibility of",
"    <em>",
"     Candida",
"    </em>",
"    spp to systemically active antifungal agents determined by CLSI M27-A3 broth microdilution MIC methods",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Species",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Antifungal agents",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Number of",
"        <br/>",
"        isolates tested",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        MIC, &micro;g/ml",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Range",
"       </td>",
"       <td class=\"subtitle2\">",
"        50 percent*",
"       </td>",
"       <td class=\"subtitle2\">",
"        90 percent*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"9\">",
"        <em>",
"         Candida albicans",
"        </em>",
"       </td>",
"       <td>",
"        Amphotericin B&bull;",
"       </td>",
"       <td>",
"        2728",
"       </td>",
"       <td>",
"        0.016-4",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flucytosine",
"       </td>",
"       <td>",
"        5208",
"       </td>",
"       <td>",
"        0.12-128",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluconazole",
"       </td>",
"       <td>",
"        5827",
"       </td>",
"       <td>",
"        0.12-128",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        3895",
"       </td>",
"       <td>",
"        0.03-8",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        5827",
"       </td>",
"       <td>",
"        0.007-2",
"       </td>",
"       <td>",
"        0.015",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        5826",
"       </td>",
"       <td>",
"        0.007-4",
"       </td>",
"       <td>",
"        0.007",
"       </td>",
"       <td>",
"        0.015",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anidulafungin",
"       </td>",
"       <td>",
"        2869",
"       </td>",
"       <td>",
"        0.007-2",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caspofungin",
"       </td>",
"       <td>",
"        2869",
"       </td>",
"       <td>",
"        0.007-0.5",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Micafungin",
"       </td>",
"       <td>",
"        2869",
"       </td>",
"       <td>",
"        0.007-1",
"       </td>",
"       <td>",
"        0.015",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"9\">",
"        <em>",
"         C. glabrata",
"        </em>",
"       </td>",
"       <td>",
"        Amphotericin B&bull;",
"       </td>",
"       <td>",
"        949",
"       </td>",
"       <td>",
"        0.03-16",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flucytosine",
"       </td>",
"       <td>",
"        1267",
"       </td>",
"       <td>",
"        0.12-128",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluconazole",
"       </td>",
"       <td>",
"        1517",
"       </td>",
"       <td>",
"        0.25-128",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        1054",
"       </td>",
"       <td>",
"        0.03-8",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        1517",
"       </td>",
"       <td>",
"        0.03-&gt;8",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        1516",
"       </td>",
"       <td>",
"        0.007-8",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anidulafungin",
"       </td>",
"       <td>",
"        747",
"       </td>",
"       <td>",
"        0.015-4",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caspofungin",
"       </td>",
"       <td>",
"        747",
"       </td>",
"       <td>",
"        0.015-&gt;8",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Micafungin",
"       </td>",
"       <td>",
"        747",
"       </td>",
"       <td>",
"        0.007-1",
"       </td>",
"       <td>",
"        0.015",
"       </td>",
"       <td>",
"        0.015",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"9\">",
"        <em>",
"         C. parapsilosis",
"        </em>",
"       </td>",
"       <td>",
"        Amphotericin B&bull;",
"       </td>",
"       <td>",
"        666",
"       </td>",
"       <td>",
"        0.25-16",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flucytosine",
"       </td>",
"       <td>",
"        1047",
"       </td>",
"       <td>",
"        0.12-128",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluconazole",
"       </td>",
"       <td>",
"        1542",
"       </td>",
"       <td>",
"        0.12-128",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        1028",
"       </td>",
"       <td>",
"        0.03-2",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        1542",
"       </td>",
"       <td>",
"        0.007-1",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        1541",
"       </td>",
"       <td>",
"        0.007-8",
"       </td>",
"       <td>",
"        0.015",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anidulafungin",
"       </td>",
"       <td>",
"        759",
"       </td>",
"       <td>",
"        0.03-4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caspofungin",
"       </td>",
"       <td>",
"        759",
"       </td>",
"       <td>",
"        0.015-4",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Micafungin",
"       </td>",
"       <td>",
"        759",
"       </td>",
"       <td>",
"        0.015-2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"9\">",
"        <em>",
"         C. tropicalis",
"        </em>",
"       </td>",
"       <td>",
"        Amphotericin B&bull;",
"       </td>",
"       <td>",
"        528",
"       </td>",
"       <td>",
"        0.06-32",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flucytosine",
"       </td>",
"       <td>",
"        759",
"       </td>",
"       <td>",
"        0.12-128",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluconazole",
"       </td>",
"       <td>",
"        1198",
"       </td>",
"       <td>",
"        0.12-128",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        839",
"       </td>",
"       <td>",
"        0.03-8",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        1198",
"       </td>",
"       <td>",
"        0.015-2",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        1197",
"       </td>",
"       <td>",
"        0.007-8",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anidulafungin",
"       </td>",
"       <td>",
"        625",
"       </td>",
"       <td>",
"        0.007-2",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caspofungin",
"       </td>",
"       <td>",
"        625",
"       </td>",
"       <td>",
"        0.007-&gt;8",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Micafungin",
"       </td>",
"       <td>",
"        625",
"       </td>",
"       <td>",
"        0.007-1",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"9\">",
"        <em>",
"         C. krusei",
"        </em>",
"       </td>",
"       <td>",
"        Amphotericin B&bull;",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        0.03-16",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flucytosine",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        0.12-128",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluconazole",
"       </td>",
"       <td>",
"        305",
"       </td>",
"       <td>",
"        8-128",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        206",
"       </td>",
"       <td>",
"        0.06-4",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        305",
"       </td>",
"       <td>",
"        0.03-4",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        305",
"       </td>",
"       <td>",
"        0.06-4",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anidulafungin",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        0.015-0.5",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caspofungin",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        0.015-1",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Micafungin",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        0.015-0.25",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"9\">",
"        <em>",
"         C. guilliermondii",
"        </em>",
"       </td>",
"       <td>",
"        Amphotericin B&bull;",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        0.06-32",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flucytosine",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        0.12-4",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluconazole",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        0.5-32",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        0.06-4",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        0.015-2",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        0.015-2",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anidulafungin",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        0.12-4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caspofungin",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        0.03-&gt;8",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Micafungin",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        0.015-2",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"9\">",
"        <em>",
"         C. lusitaniae",
"        </em>",
"       </td>",
"       <td>",
"        Amphotericin B&bull;",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        0.06-16",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flucytosine",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        0.12-128",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluconazole",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        0.12-64",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        0.03-1",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        0.015-1",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        0.007-1",
"       </td>",
"       <td>",
"        0.007",
"       </td>",
"       <td>",
"        0.015",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anidulafungin",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        0.06-1",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caspofungin",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        0.03-1",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Micafungin",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        0.03-1",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CLSI: Clinical and Laboratory Standards Institute; MIC: minimum inhibitory concentration.",
"     <br>",
"      * MIC encompassing 50 percent and 90 percent of isolates tested, respectively.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Amphotericin B MICs determined by Etest.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Pfaller, MA, Boyken, L, Hollis, RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46:150.",
"       </li>",
"       <li>",
"        Pfaller, MA, Messer, SA, Boyken, L, et al. In vitro activities of 5-fluorocytosine against 8803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 2002; 46:3518.",
"       </li>",
"       <li>",
"        Pfaller, MA, Messer, SA, Boyken, L, et al. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J Clin Microbiol 2004; 42:3137.",
"       </li>",
"       <li>",
"        Pfaller, MA, Boyken, L, Hollis, RJ, et al. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9359 isolates tested by Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol 2005; 43: 3807.",
"       </li>",
"       <li>",
"        Pfaller, MA, Messer, SA, Boyken, L, et al. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J Clin Microbiol 2008; 46:551.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_44_36559=[""].join("\n");
var outline_f35_44_36559=null;
